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ABSTRACT
Over the last few decades, liposomes have generated a lot of interest as drug delivery
vehicles to address the need for providing both increased therapeutic efficacy and decreased
systemic exposure, simultaneously. The challenge of increasing drug accumulation at diseased
sites, without compromising the integrity and stability of the liposomal carrier during circulation,
has been met with two possible solutions: (1) active targeting and (2) active triggering. To
achieve selective and site-specific delivery of drugs to tumors, active triggering methods have
been developed wherein a responsive element is incorporated into the liposomal bilayer, which
causes destabilization of the liposome upon exposure to the proper stimulus. Endogenous stimuli
can offer high specificities and sensitivities, if appropriate trigger groups exist so as to take full
advantage of diseased site characteristics.
The research described herein involved the synthesis of redox-active, quinone-lipid
conjugates that were prepared into liposomes for the containment and subsequent
triggered release of encapsulated cargo. Development of said system required (1) the synthesis
and then characterization of various simple quinones and quinone propionic acids by cyclic
voltammetry

and

X-ray

crystallography

and

(2)

the

preparation

of

substituted

quinone-dioleoylphosphatidylethanolamine lipids into liposomes and evaluation of their
triggered release behaviors by fluorescence emission spectrometry.
Elucidation of the electrochemical properties of simple quinones and quinone propionic
acids revealed a correlation between quinone substitution and reduction potential, meaning that
the electronics of the quinone trigger can be adjusted through their chemical structure. X-ray
crystallography showed a highly distorted quinone ring proximal to the trimethyl-locked
propionic acid side chain.

xv

Upon introduction of a chemical reducing agent, the four different substituted
quinone-dioleoylphosphatidylethanolamine liposomes each displayed distinctive release
behaviors, as indicated by the time-dependent increase in fluorescence signal as encapsulated
calcein was released below its self-quenching concentration. The individual release profiles
demonstrate the influence of quinone substitution on the triggered response of these redox-active
liposomes; thus, realizing the programmed delivery of liposomal contents through active
triggering. The information learned from this research project provides a solid foundation for
exploring the triggered release of these redox-active liposomes by NAD(P)H:quinone acceptor
oxidoreductase type 1, an over-expressed reductase enzyme in numerous cancer cell lines.

xvi

CHAPTER 1
INTRODUCTION
1.1

Research Goals and Aims
The goal of this research is the development of redox-active liposome delivery agents

with highly controllable stimuli-responsive behavior. In particular, liposomes composed of a
fusogenic phospholipid, dioleoylphosphatidylethanolamine (DOPE), covalently coupled to a
functionalized, electrochemically active quinone (Q) stabilizer/trigger moiety are to be prepared
to achieve a delivery system that can encapsulate and then selectively/specifically release its
contents upon interaction with a stimulus (reducing agent or reductase enzyme).
The ability to contain, transport, and selectively deliver cargo at a given location or time
is of paramount importance to a variety of applications, such as microfluidics, assays, diagnostics
and sensors, separation techniques, and drug delivery, where micro- to nano-scale control and
manipulation is the name of the game. As a result, a variety of different delivery systems (e.g.
micelles, polymeric micelles, dendrimers, polymer-drug conjugates, liposomes) have been
designed in an attempt to meet this demand. Liposomes have especially generated a lot of
interest as drug delivery vehicles to address the need for attaining both increased therapeutic
efficacy and decreased systemic exposure, simultaneously.
Liposomes offer several advantages as drug delivery containers due to their
versatility—which is mainly a result of their amphiphilicity, general size (µm to nm), and
molecular framework. The hydrophobicity of many active pharmaceutical ingredients (APIs)
makes their administration in the human body difficult to impossible without the aid of a
solubilizing agent. The lipophilic environment of the liposomal bilayer provides adequate seat
for hydrophobic APIs during their transport (e.g. AmBisome), while the internal aqueous core
1

can accommodate more hydrophilic guests (e.g. Doxil, DaunoXome). Moreover, the micro- to
nanometer size of liposomes also makes possible the containment of APIs with a wide range of
sizes and at variable doses (amount of encapsulated cargo). The wide variety of lipids, lipid
stabilizer/trigger groups, targeting moieties (e.g. peptides, antibodies), and non-immunogenic
agents (e.g. poly(ethylene glycol) a.k.a. PEG, chitosan) that can constitute a liposome’s
molecular framework makes possible highly specific, stimulus-actuated delivery of contents at a
desired place or time.1 However, the full potential of liposomes is still being realized as more
information about the microenvironment and differentiating characteristics (from healthy tissue)
of tumors is being discovered.
The evolution of liposomes as drug delivery vehicles can be seen in the marketplace, as
there have been 11 liposomal drug formulations approved for clinical use in the past 15 years,
with 6 more currently in clinical development.2 In 1995, the first liposomal drug packaging was
approved by the U.S. Food and Drug Administration (FDA); Doxil, a PEG-protected excipient
for doxorubicin (chemotherapeutic), was marketed for the treatment of HIV-related Kaposi’s
sarcoma and has also been approved in the last decade to treat metastatic breast and ovarian
cancer.2 Composed of cholesterol (for added bilayer stability) and a mixture of hydrogenated
soy phosphatidylcholine and PEGylated phosphoethanolamine lipids, Doxil has dramatically
increased the drug survival time (circulation half-life) and the drug concentration at the diseased
site, resulting in it being six times more effective than free doxorubicin.3
The other currently marketed liposomal drug formulations (e.g. AmBisome,
DaunoXome, and DepoCyt) and Doxil deliver their payloads by passive diffusion or non-specific
degradation of the lipid bilayer.

Basically, the drug-loaded liposomes circulate in the

bloodstream until they eventually accumulate at the diseased site via the enhanced permeation
and retention (EPR) effect.4-7 In the interim during circulation, the non-specific means by which
2

the bilayer destabilizes and breaks down causes some of the free drug and lipids to leak out into
normal, healthy tissue; this leads to harmful side effects (i.e. mucositis, hand-foot syndrome).
While liposome-based transport of cytotoxic APIs does significantly improve the
tumor-to-normal tissue drug ratio and lowers systemic exposure versus the free drug, this passive
release mechanism still leaves something to be desired. Ideally, the liposomal bilayer should be
stable enough so that its cargo is well protected from the environment (and vice versa), but then
destabilize only once the target site is reached. Seemingly a dichotomy, the price for developing
highly stable liposomes is often a decrease in the rate and/or amount of APIs released at the
desired location, thus reducing medicinal efficacy.
In response, liposome drug delivery research has begun to navigate two general routes
that address the need for increased drug accumulation without compromising the integrity and
stability of the liposomal carriers: (1) active targeting and (2) active triggering.3 Nearly all
nanoparticle-based therapeutics use the EPR effect as a guiding principle; therefore, active
targeting cannot be separated from passive targeting (i.e. the EPR effect), because active
targeting occurs after passive accumulation has already happened.5 Owing to this caveat, active
triggering and the various approaches thereof will be discussed, and it is a major component of
the goal of the research presented in this dissertation.
Programmed delivery of liposomal contents is typically achieved by having a triggerable
functionality in the molecular design of the bilayer, that upon application of the proper “trigger”
stimulus, either perturbs the permeability of the bilayer or completely disrupts its stability.8
Stimuli that trigger liposomal contents delivery are grouped into two general categories:
exogenous and endogenous triggers.8

External (exogenous) stimuli include radiation and

temperature, which inherently require localization of the target area prior to treatment, thus
preventing their use in cases where the diseased site is not necessarily known (e.g. early-stage
3

and metastatic cancers).8 In addition, liposome systems that utilize internal (endogenous) stimuli
(i.e. pH and enzymes) to trigger the release of their cargo are more attractive for drug delivery,
because they offer local control over payload delivery. By making use of certain over-expressed
or differentiating characteristics of a disease as an internal stimulus, these liposomal systems can
be programmed to intrinsically trigger upon interacting with that stimulus, thus achieving sitespecific drug delivery.
Liposomes that are pH-sensitive take advantage of the increasingly acidic environment of
cancerous tumors as the tumor interior is penetrated. The extravasation of these liposomes,
especially those with targeting ligands attached to their periphery, can lead to liposome
internalization into cancerous cells via endocytosis where the endosomal/lysosomal pH is around
5 or below, much lower than physiological pH 7.4.8 Therefore, the design of pH-triggered
liposomes has primarily utilized fusogenic lipids so that escape from the endosomes is possible,
which enables drug delivery directly into the cytoplasm and prevents the inevitable lysosomal
degradation of the drug-loaded liposomes. Fusogenic lipids undergo a phase transition, from a
lamellar bilayer (Lα) to type II inverted hexagonal (Hα or HII) micelles, that results in
destabilization of the liposome and delivery of its contents.8 Consequently, fusogenic lipids (e.g.
phosphatidylethanolamines) have become a benchmark in the design of pH-sensitive liposomal
formulations, which also include any combination of stabilizing lipids, polymers, amphiphilic
molecules, and/or targeting ligands (e.g. antibodies, peptides). The evolution of pH-sensitive
liposomes has lead to highly complex, multifunctional systems whose behavior has not yet been
well characterized, especially in vivo.3
The development of enzymatically-triggered liposome delivery agents has evolved
naturally from the already abundant literature on enzyme-actuated prodrugs and bioactivable
drugs.9

Currently, this young field of enzyme-activated liposome opening is based on a small
4

number of enzymes compared to the extensive library of enzymes used to activate prodrugs.
Most of the literature surrounding enzyme-responsive liposomes is based on use of
phospholipase A2 (PLA2) and matrix metalloproteinase (MMP) to trigger liposome opening;1,10-16
however, a few other enzymes have also been explored: elastase,17 phospholipase C,18 and
alkaline phosphatase.19 By exploiting enzymes that are intrinsically over-expressed in tumors,
this drug delivery method has the potential to selectively and site-specifically dispense its
liposome-encased chemotherapeutic cargo at cancerous regions in the body. As Andresen et al.
discuss in a recent review of this topic, a very interesting aspect of enzyme-triggered, PEGylated
liposome systems is that enzymes seem to be capable of penetrating the protective PEG polymer
sheath.1 Reports utilizing PLA2 (14 kDa) and MMP (72–92 kDa) approaches show that these
enzymes can apparently reach and hydrolyze the lipids or peptides buried below the PEG sheath
layer, which is quite a serendipitous outcome in order for this strategy to be successful.1,20-23
By

extension,

the

medium-sized

enzyme

that

our

liposome

delivery

system

is

targeting—NAD(P)H:quinone acceptor oxidoreductase type 1 (NQO1, 62 kDa)—should also be
able of penetrating PEG coronas. Human NQO1 is a reductase that is structurally suited for
quinone-type substrates and is also upregulated in tumors.24-25 By taking advantage of its
inherent structural specificity for quinones, hNQO1 can be further tuned to our
quinone-functionalized liposomes by adjusting the electronics of the quinone molecule so as to
obtain optimum enzyme-substrate interaction, leading to controlled liposome contents delivery.
The first aim of this research is the creation of a family of tunable, redox-responsive
quinone-dioleoylphosphatidylethanolamine (Q-DOPE) lipids. An important intermediate in the
synthetic pathway to the target Q-DOPE lipids is a water-soluble compound, quinone-propionic
acid (Q-COOH), which allowed the investigation of its electrochemical properties by cyclic
voltammetry (CV) in aqueous media. Structurally similar, simple quinones (those with no side
5

chain), and others deemed relevant, were also synthesized or purchased in order to see the effect
of the propionic acid side chain on the electrochemical properties and also to (hopefully) support
the trend(s) observed for the Q-COOH series.

The reduction potentials of the “model”

Q-COOHs should equal that of the corresponding Q-DOPE lipids, because any functional
changes to the end of the side chain are too far away from the quinone ring to have any
substantial electronic influences.
Understanding how the various quinone substituents affect the electronics of each
molecule is important in the development of our redox-triggered Q-DOPE liposomes, whose
activation and rate of destabilization (payload delivery) is dependent on the electronic structure
of the quinone moiety. X-ray crystallographic analysis of all applicable (crystalline) Q-COOHs
was conducted to investigate any structural variables (i.e. quinone substituents and trimethyl
lock) that could influence their electrochemical behavior. A decrease in quinone ring planarity
due to ring strain26-38 leads to localization of the quinone π-system, and this change in electron
distribution should be reflected in the electrochemical data (more negative reduction potentials).
The information learned about the electronics and structure of these Q-DOPE lipid precursors is
important in designing our triggerable liposome delivery system in order to exert molecular
control over its activation and destabilization behavior.
Furthermore, enzyme-substrate reactivity and specificity can be optimized according to
these electrochemical trends; the catabolism of the Q-COOHs by hNQO1 using enzyme kinetics
assays has been studied by a colleague in our research group using quinone substrates that were
chosen based on their reduction potentials. Through careful selection of the substituted quinone
moiety, in conjunction with its inherent structural reactivity and specificity for hNQO1, our
tunable liposomes can also be targeted towards hNQO1 to minimize cross-reactivity with other
enzymes or potential adventitious reducing agents in the body. Based on the results from the
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CV, X-ray crystallography, and enzyme assay experiments, 4 different Q-DOPE lipids were
synthesized: QBr–DOPE (6c), QH–DOPE (6a), QMe–DOPE (6b), and QnPrNH–DOPE (6d).
The second aim of this research is examination of the encapsulation and triggered release
behavior of the 4 selected Q-DOPE liposomes using fluorescence spectroscopy. The various
Q-DOPE liposomes were prepared according to the “lipid thin-film and extrusion” method.39-41
To investigate the hosting and release properties of the various Q-DOPE liposomes, calcein (a
fluorescent dye) was loaded into the liposomes above its self-quenching concentration (Cquench),
and then gel-filtration chromatography was used to separate and remove the non-encapsulated
calcein from the loaded liposomes. Sodium dithionite (a powerful reducing agent) was added to
initiate the destabilization of the liposomes by reduction of the quinone to the hydroquinone,
followed by spontaneous intramolecular cyclization and elimination of the lactone, resulting in
fusogenic (unstable) peripheral regions of the liposomes. After contact-driven rupture of these
fusogenic liposomes, the encapsulated calcein was released at a concentration below its Cquench,
and the increase in fluorescence signal was monitored using emission spectroscopy. To establish
what qualifies as 100% release, Triton X-100 (a detergent) was added to completely and
non-specifically disrupt the liposomal bilayer. The average sizes and zeta potentials of these
Q-DOPE liposomes were also measured in order to provide information that may help explain
the results/observed trends from the fluorescence experiments. The QnPrNH-DOPE liposomes
were of particular interest, due to the possibility of the n-propylamino group being protonated,
which would have a considerable impact on the overall charge of the bilayer.
The utility of these redox-responsive liposome delivery agents ranges from their use in
drug delivery to achieve selective, site-specific transport of chemotherapeutics and/or imaging
agents in the human body, to the controlled release of various reagents in microfluidic devices
and immunoassays.
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1.2

Importance of “Smart” Nanosized Delivery Systems

1.2.1

Applications
The ability to contain, transport, and selectively deliver cargo at a given location or time

is of paramount importance to a variety of applications such as microfluidics, assays, diagnostics
and sensors, separation techniques, and drug delivery, where micro- to nano-scale control and
manipulation is a key element to their success. By 2015, the U.S. National Science Foundation
projects that the nanotechnology market will be worth U.S. $1 trillion.5
One of the major obstacles involved in the employment of microfluidic devices is the
ability to achieve temporal and spatial delivery and sufficient mixing of reagents within the
channels of said devices. To address this issue, Vreeland and Locascio used thermally-triggered
liposomes to selectively deliver reagents in a microfluidic device, resulting in highly efficient
mixing with an average time of 110 ms.42

Microfluidics also benefit from the use of

nanocontainers to attain signal amplification, which is especially pertinent when their channels
host (bio/immuno)assays and (bio/immuno)sensors. Genç et al. developed an amperometric
immunosensor that employed thermosensitive liposomes for the ultrasensitive detection of a
cancer biomarker.43 The detection limit was lowered by two orders of magnitude, compared to
that of the traditional immunosensor, and up to 11-fold amplification in signals was achieved as
well.43

Similarly, other reports have utilized liposomes for signal enhancement in various

assays44-47 and sensors.47-48

Particularly with cancer diagnosis, nanotechnology affords the

possibility to realize rapid, more sensitive and selective detection of cancer biomarkers with
high-throughput systems.48
In cancer diagnostics, magnetic resonance imaging (MRI) is one of the most common
technologies used; however, it typically cannot detect entities with dimensions smaller than a
few centimeters.48 To improve the sensitivity and limit of detection (LOD) of MRI, dendrimers
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have been investigated as advanced contrast agents for highlighting cancerous tissue in the MR
images.48 Majoros and coworkers have recently reviewed various dendrimer systems being
explored for improving cancer diagnostics and therapy.49
Even separations and extractions benefit from the use of nanocontainers to enhance
selectivity, sensitivity, and lower detection limits.

Micellar electrokinetic chromatography

(MEKC) is used in capillary electrophoresis (CE) to lower the limit of detection and enhance
sensitivity by separating (electrically neutral) analytes that partition into micelles
(pseudo-stationary phase) from the aqueous mobile phase.50

Other micelle-based

preconcentration techniques are used, such as analyte focusing by micelle collapse (AFMC) in
CE,51 cloud point extractions,52-53 and micellar-enhanced ultrafiltration (MEUF).52 The latter
two techniques have been used to separate and preconcentrate metal ions,52 and cloud point
extraction has also been applied to isolate biological analytes (e.g. proteins, enzymes) for
purification and to extract and preconcentrate environmental analytes (e.g. polychlorinated
dibenzo-p-dioxins, polycyclic aromatic hydrocarbons, pesticides).53 While nanocontainers have
significantly improved the analytical techniques discussed here, their application in the realm of
drug delivery is where much of the current research lies.
The disease that most desperately needs selective, site-specific drug delivery is cancer,
which is a leading cause of death around the world. Between 2005 and 2015, the World Health
Organization estimates that 84 million people will die of cancer and that deaths from cancer are
expected to rise to over 11 million in 2030, worldwide.5,54 A multifactorial disease, cancer arises
from genetic mutations that control division, proliferation, differentiation, and cell death that
disrupt normal cell metabolism and tissue homeostasis.55 These gene mutations result from
genetic defects and/or bodily exposure to environmental, mutagenic agents (e.g. tobacco,
alcohol, radiation).48 At the early onset of cancer, normal cells undergo a progressive series of
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abnormalities at the cellular level that lead to uncontrolled and continuous proliferation of cancer
cells, which results in tumor formation and can also lead to metastases.55 The two major origins
of cancer are activation of oncogenes and deactivation of tumor suppressor genes (TSGs).
Oncogenes are responsible for regulating cell growth, proliferation, and/or differentiation, and so
over-activity of oncogenes leads to excessive cell growth and division, leading to tumor
masses.48

Tumor suppressor genes police any “illegal” or unnecessary cell growth and

development by slowing or stopping cell division, so any mutations to TSGs also result in tumor
formation.48
Oncology is one of the primary branches of medicine utilizing drug targeting, and some
of the various cancer therapies used with nanoparticles include chemotherapy, immunotherapy,
radiotherapy, photodynamic therapy, and others.55 Perhaps the most well-known of these is
chemotherapy, which in combination with nanoparticles, delivers cytotoxic agents to cancerous
sites in the body. Some of these cytotoxic APIs include doxorubicin, paclitaxel, 5-fluorouracyl,
irinotecan, camptothecin, and methotrexate.55-57 Protection of these drugs from the physiological
environment (and vice versa), until the target site is reached, is fundamental toward achieving
both increased efficacy and low systemic exposure.
On that note, pharmacokinetics and pharmacodynamics play very important roles in
nanoparticle-based drug delivery. Pharmacokinetics is simply defined as the effects of the body
on the drug, while pharmacodynamics is the effects of the drug on the body. Upon intravenous
injection, drugs go through adsorption, distribution, metabolism and elimination (ADME), and
an optimum ADME process depends mostly on the properties of the drug (i.e. molecular weight,
shape, charge, aqueous solubility).55

From a nanoparticulate-DDS perspective, both the

pharmacokinetics and pharmacodynamics can be improved if the DDS is non-immunogenic
(“invisible” to the body) and favorably alters the biopharmaceutic and pharmacokinetic
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properties of the drug by allowing them to be delivered intravenously (in higher doses than the
free drug) and site-specifically.55 In addition to the properties of the encapsulated drug, the
pharmacological profile of liposomal drug formulations is also dependent upon the ADME of the
liposome excipient, the drug release rates, and the total amount of drug released.57 Thus, the
therapeutic efficacy of the encapsulated drugs mainly depends on the pharmacokinetics and
tissue distribution of the nanoparticulate-DDS.55,57 Ideal delivery vehicle characteristics include
the following: (1) protection of drug cargo from the environment (and vice versa),
(2) containment of a wide variety of drug molecules, (3) improvement of tumor-to-normal tissue
drug ratios, (4) transportation/delivery of variable dose amounts, (5) controlled and site-specific
delivery of contents, and (6) biocompatibility/biodegradability.5
1.2.2

Types of Drug Delivery Systems (DDS)
Not surprisingly, a large majority of the research being done today in the field of

nanotechnology is geared towards improving the selective and site-specific delivery of reagents,
particularly those that will enhance the diagnostics, sensing, monitoring, and/or treatment of a
disease. Among these applications in the healthcare industry, the careful delivery of drugs to
diseased sites is of particular interest, as is evidenced by the breadth and variety of drug delivery
systems (DDS). While a myriad of DDS are discussed in the literature, only a select few are
delineated here.
Traditional micelles, or “surfactant micelles,” are characterized by an inner hydrophobic
core that is defined by an outer hydrophilic corona.55,58 Surfactant molecules spontaneously
assemble into micelles only above the critical micelle concentration (CMC), forming these
aggregate structures of 5–100 nm in diameter.55

In the late 1960s, researchers began to

investigate the use of micelles as drug carriers, because their properties can be easily modified
(e.g. size, charge, surface properties) and are pharmacologically viable for distribution in the
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body.55,58-59 Micelles possess many of the same advantages as liposomes, such as the ability to
contain both hydrophilic and hydrophobic drugs, protection of encapsulated cargo, a degree of
functionality/control, to name a few. In fact, several micellar-based formulations are currently in
clinical trials, including NK105 (paclitaxel, Phase II), NC-6004 (cisplatin, Phase I/II), and
SP1049C (doxorubicin, Phase III).55 The two major disadvantages of micelles that limit their
application as DDS are (1) their smaller size, that limits the amount of encapsulated cargo, and
(2) their relative instability, especially in biological fluids, where the CMC decreases, resulting
in premature leakage of the drugs.55 As a result, polymer-based micelles have gained much
attention to fill the voids of these traditional micellar systems.
By comparison, polymeric micelles (PMs) have CMC values several orders of magnitude
much lower than traditional micelles, making them much more stable and less susceptible
towards dilution.58-62 For example, an aqueous solution of sodium dodecyl sulfate (surfactant)
has a CMC of about 2300 mg L−1,63 versus a poly(saccharide) PM whose CMC is only about
5 mg L−1,58 which amounts to nearly a 500-fold decrease. Polymeric micelles are prepared from
amphiphilic diblock, triblock, or even graft copolymers which form 10–100 nm aggregates
(above the critical aggregation concentration, CAC) are composed of an inner hydrophobic core
and an outer hydrophilic shell.58,60

Some common hydrophilic polymers used in PMs are

poly(ethylene glycol), poly(N-vinyl-2-pyrrolidone), and poly(vinyl) alcohol, while the
hydrophobic core most often consists of polyesters and poly(amino acids).62,64-65

PMs

masquerade under various aliases in the literature: micelles, nanospheres, core-shell
nanoparticles, micelle-like nanoparticles, nanocapsules, and polymersomes.61

PMs offer a

degree of flexibility, compared to their low-molecular-weight counterparts, in that both the
hydrophilic and hydrophobic polymers can be engineered so as to allow attachment of a wide
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variety of drug molecules; furthermore, PMs can be made to actively target certain diseased sites
by attaching targeting moieties onto their peripheral polymer chain ends.58,61
Dendrimers are monodisperse, highly-branched, three-dimensional structures composed
of three distinctive architectural components: (1) an interior core onto which (2) “generation”
layers of repeating molecular units are radially attached and then (3) terminated by some
functionality that defines the exterior of the tree-like dendrimer.56,61,66 Most often composed of
poly(amido amine) and poly(propylene imine), dendrimers range from 1–100 nm3 in size and
become increasingly more rigid and globular as the generation is increased.56,61,66

For

biomedical applications, fourth-generation dendrimers (and higher) are used and have found
great applicability in drug delivery and as imaging agents,49 transporting bioactive cargo
encapsulated in the interior layers or covalently bound to the surface of the dendrimer.56,61,66
VivaGel (Starpharma) is a dendrimer formulation in clinical development as a topical
microbicide to prevent the spread of certain sexually transmitted diseases.49,61 The architecture
of dendrimers (e.g. size, shape, branching, functionalities) can be controlled to offer desired
properties pertinent to a given application, much like PMs.56,66-67 However, the main drawback
of dendrimers as DDS is the rapid and uncontrollable release of their encapsulated contents
which has hindered their success in clinical trials.56
Polymer–drug conjugates are essentially macromolecular prodrugs that are composed of
drug molecules that are covalently linked to a biocompatible, water-soluble polymer (between
10,000–100,000 MW) through biodegradable bonds.61,68 Some examples of commonly used
polymers are poly(ethylene glycol) a.k.a. PEG, N–(2–hydroxypropyl)methacrylamide or HPMA,
and poly(lactide–co–glycolide) a.k.a PLGA.69

In aqueous environments, the polymer-drug

conjugates assemble into a micelle-like state that have 5–100 nm dimensions.61,69 Examples of
such therapeutics include polymer-drug and polymer-protein conjugates, and even PMs and
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dendrimers that contain covalently bound drugs. The most promising pharmaceutical candidates
in clinical trials are the polymer–protein and polymer–anticancer drug conjugates; however,
several formulations are currently undergoing clinical evaluation.68-69 One example of a quite
successful polymer-drug conjugate in Phase III clinical trials is poly(L-glutamic acid)–paclitaxel
(CT-2103, Xyotax).68

Polymer-drug conjugates can be actively targeted to tumors by

incorporating ligands into their formulation.68-69 In the medical arena, polymer-drug conjugates
are being used as new targeted anti-angiogenic therapies and as modulators of cellular apoptosis
(i.e. single pro-apoptotic agents in cancer or anti-apoptotic agents in ischemia).61

Major

drawbacks of these DDS are their limited cargo-carrying capacity and the fact that the drug,
itself, is chemically modified through its covalent attachment to the polymer carrier, an alteration
that can affect its efficacy and mechanism of action compared to the free drug.69
As more information is learned about the physiology of certain diseases (most notably,
cancer) and great strides are made in the advancement of nanotechnologies, researchers are
beginning to better identify and engineer critical components in drug delivery systems. As the
search for a “magic bullet” continues, a few drug delivery vehicles seem to be within in reach of
attaining this elusive status. Liposomes, in particular, are a paradigm in the realm of smart drug
delivery systems and have been speculated as a potential frontrunner for providing all-inclusive
drug delivery.70
1.3

Liposomes, the “Quintessential” DDS?

1.3.1

Advantages
Especially in the last 30 years, liposomes have generated a lot of interest as drug delivery

vehicles to address the need for providing both increased therapeutic efficacy and decreased
systemic exposure, simultaneously. They were the first nanoparticle-based DDS to reach the
market and have one general advantage over other types of DDSs: with respect to drug delivery,
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the knowledge about how to encapsulate drugs into liposomes and their stability and toxicity is
substantially higher in this field.71

Liposomes offer several advantages as drug delivery

containers due to their versatility, which is mainly a result of their amphiphilicity, general size
(µm to nm), and molecular framework.
The hydrophobicity of many APIs makes their administration in the human body difficult
to impossible without the aid of a solubilizing agent.

The lipophilic environment of the

liposomal bilayer provides adequate seat for hydrophobic APIs during their transport (e.g.
AmBisome), while the internal aqueous core can accommodate hydrophilic guests (e.g. Doxil,
DaunoXome).

Compared to drug-conjugates and other nanoparticles that contain covalent

attachments of drug molecules, liposomes undergo less rigorous standardization because the
actual drug is unmodified and merely carried within the liposome itself. Moreover, highly
cytotoxic drugs are contained and shielded from the environment, thereby lowering systemic
exposure and increasing/maintaining the therapeutic index of the drug by preventing its
degradation by the body. Larger doses of the APIs can be administered as well because of the
protection afforded by the liposome from the body during circulation. The micro- to nanometer
size of liposomes makes possible the containment of APIs with a wide range of sizes and at
variable doses (amount of encapsulated cargo).
In the majority of the cases, their size also allows them to reach both localized and
systemic sites, because liposomes fall into the optimum size range of 50–150 nm to exploit the
enhanced permeation and retention (EPR) effect but avoid extravasation into healthy tissues.72
The wide variety of lipids, lipid stabilizer/trigger groups, targeting moieties (e.g. peptides,
antibodies), and non-immunogenic agents (e.g. poly(ethylene) glycol (PEG), chitosan) that can
constitute a liposome’s molecular framework makes possible highly specific, stimulus-actuated
delivery of contents at a desired place or time.1
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The special storage and handling of liposomes, because of their short shelf life, is one
disadvantage of using them as DDSs. In aqueous solution, hydrolysis and oxidation of the
phospholipid chains can occur, leading to degradation of the liposome.47 Other factors, such as
the chemical composition of the membrane, the nature of the entrapped cargo, and the pH and
temperature of the storage solution impact the stability of liposomes.47 To this end, liposomes
are normally stored at 4 °C under an inert gas.47
Despite these few drawbacks, the full potential of liposomes is still being realized as
more information about the tumor microenvironment is being discovered. The versatility of
liposomes, coupled with the differentiating characteristics of tumors, has led to a growing
number of liposomal formulations in the marketplace and in clinical trials, suggesting that
liposomes have yet to reach their full potential.
1.3.2

1st– and 2nd–Generation Liposomes
Liposomes were first recognized by Bangham and co-workers73 in 1965, even though

lipid researchers in the mid-1800s were studying these colloidal structures, known at the time as
lecithin emulsions, sols, and suspensions.74 However, these earlier researchers did not realize
that the colloidal membranes formed by aqueous lecithin phases were self-closed and contained
inner compartments, a characteristic that was later recognized and denoted as large multilamellar
liposomes (or “Bangasomes”).74 The internal aqueous cores are separated from the surrounding
bulk solution by lipid membranes.74 This first generation of liposomes are characterized as
spherical particles composed of a phospholipid membrane(s) that can host both hydrophilic (in
the aqueous interior) and hydrophobic (in the bilayer) guests, such as drug molecules.3 Much
later in the late 1980s to early 1990s, liposomes as drug delivery systems suffered much criticism
and doubt when in vivo studies of liposome-encapsulated formulations were unsuccessful,
primarily due to their rapid uptake in the reticuloendothelial system (RES) and subsequent
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elimination from the body.74 The RES, also known as the mononuclear phagocytic system
(MPS), commands an arsenal of opsonin proteins (e.g. IgG antibodies, fibrinogen, complement
protein C3b) that “mark” foreign particles to be phagocytosed by phagocytes and circulating
monocytes in the liver, spleen, bone marrow, and lymphatic tissue, leading to elimination of
these particles from the body.55,75-79
The solution to reduce the rapid clearance of liposomes from the body by the RES gave
birth to the second generation of liposomes: sterically stabilized liposomes that contain a
protective polymer coating on the periphery, are more adept at avoiding capture by the body’s
immune system.3,6-7,78-81 The most popular polymer coating used to protect liposomes from the
RES is poly(ethylene glycol) a.k.a. PEG, of at least 2,000 MW, and these modified liposomes are
called PEGylated, PEG-protected, or Stealth liposomes.71,76-77 While the exact mechanism by
which the PEG corona protects liposomes from opsonization is still not fully understood,75,77 two
possible explanations have been posed: (1) PEG acts as a shield, sterically hindering the
approach and adsorption of opsonin proteins to the liposome surface; and (2) Certain serum
proteins adsorb to the liposome surface, possibly partly caused by the PEG corona, and act as
nonspecific dysopsonins that fortuitously decrease the adsorption of opsonins.71,77,81

More

information about protein adsorption to liposomes must be acquired in order to determine exactly
how PEG protects liposomes, and other nanoparticles, from the RES.71 As a side note, Yoo et al.
have reviewed some of the drawbacks of PEGylation and also discuss recent developments to
increase the circulation of nanoparticles in the body.82
In general, as a result of PEGylation, these stealth liposomes have been shown to remain
in circulation for increased periods of time compared to their first-generation counterparts, which
allowed them to fully harness what is known as the enhanced permeability and retention (EPR)
effect. Longer circulation times are required in order for liposomes to reach and amass at
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diseased sites (i.e. tumors, inflamed tissue) possessing certain structural abnormalities that are
characteristic of the EPR effect. Due to extensive angiogenesis and the chaotic nature of cancer,
the environment of tumors is plagued by a high density of defective blood vessels that are dilated
and disordered.4-6,75,83 This leaky vasculature (pore dia. ~100–2000 nm) is more permeable to
macromolecules and molecular assemblies (e.g. liposomes), versus normal healthy vessels (pore
dia. ~2–6 nm), leading to their preferential accumulation in tumor tissues.4

Additionally,

inefficient lymphatic vessels increase the retention of these larger molecular entities within the
tumor interstitium because of poor drainage.4-5 Thus, the optimum size so as to maximize the
EPR effect for liposomal DDSs ranges between 10–150 nm in diameter to avoid leaking into
healthy tissue and elimination by the kidneys (> 10 nm) and the liver (< 100 nm).5,72
Besides avoiding the RES and dodging healthy tissues, the ideal sizes of liposomes also
provide another advantage to their use in drug delivery. High tumor interstitial fluid pressure
(IFP) is a potential barrier for some DDSs, particularly those that are smaller in size. High IFP in
tumors results from interstitial hypertension inside tumors due their poor lymphatic (drainage)
system and vascular hyperpermeability.5,72 Movement of fluid is centralized at the core of solid
tumors and flows outward toward the periphery, causing the IFP to be slightly higher as a
function of depth in tumors.5,72 Drug-loaded nanocarriers, such as liposomes, are less affected
by high IFP in tumors because their larger size can effectively fight against the opposing fluidic
current.5,72
As a result of more stable in vivo formulations, 11 clinically-approved liposomal
formulations have been developed in the past 15 years, with 6 others currently in clinical trials.2
As a single therapeutic nanocarrier, liposomes have primarily been developed for cancer
treatment.84 Doxil, Myocet, and DaunoXome are all currently-marketed liposomal formulations
used in a variety of cancer therapies, while some others are still in clinical trials.84 The first
18

liposomal drug packaging approved by the FDA and the “go-to” example of a successful
liposome-based DDS is Doxil. Based on a PEGylated excipient for Doxorubicin, Doxil was
initially approved and marketed for the treatment of HIV-related Kaposi’s sarcoma, and was
approved (2001) and has been used to treat metastatic breast and recurrent ovarian cancer. It is
composed of cholesterol for added bilayer stability and a mixture of hydrogenated soy
phosphatidylcholine and PEGylated phosphoethanolamine lipids. With its PEG protection from
the RES, Doxil has dramatically increased the circulation half-life time and drug concentration at
the diseased site via the EPR effect, amounting to it being six times more effective than free
Doxorubicin.3
A pH gradient across the bilayer is used to load Doxorubicin into these liposomes, and
this transmembrane pH gradient is hypothesized to become disrupted once Doxil liposomes
reach the tumor site, releasing doxorubicin into the local area.71 There exists a delicate balance
in terms of the stability of Doxil liposomes in circulation versus in the tumor, as the
encapsulation/release of doxorubicin relies simply on a proton gradient.71 The passive release
mechanism by which the currently-marketed liposomal formulations (e.g. Doxil, AmBisome,
DaunoXome, DepoCyt, etc.) deliver their payload involves passive diffusion or non-specific
degradation of the bilayer. Due to this non-specificity of destabilization, some of the free drug is
able to leak out into healthy tissue during circulation, leading to harmful side effects and
decreased concentration of the drug at the diseased site. While liposome-based transport of
cytotoxic drugs does significantly improve the tumor-to-normal tissue drug ratio and lowers
systemic exposure versus the free drug, this passive release mechanism still leaves something to
be desired.
Ideally, the liposomal bilayer should be sufficiently stable so that its cargo is well
protected from the environment (and vice versa) but then destabilize only when the target site is
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reached. Seemingly a dichotomy, the price for developing highly stable liposomes is often a
decrease in the rate and/or amount of APIs released at the desired location, thus reducing
medicinal efficacy. In response, liposome drug delivery researchers have pioneered two general
routes that address the need for increased drug accumulation without compromising the integrity
and stability of the liposomal carriers: (1) active targeting and (2) active triggering.
1.4

Stimuli-responsive Liposomes

1.4.1 Active Targeting
Active targeting is one route employed to increase the site-specific delivery of drugs to
tumors by facilitating both (1) direction to cancerous cells and (2) drug retention by preventing
retrograde movement of the liposomes back into the bloodstream due to high interstitial fluid
pressure (IFP).3

It involves utilizing certain over-expressed characteristics of tumors (e.g.

integrin, folate and transferrin receptors) to enhance liposome accumulation in tumor tissue by
incorporating targeting moieties onto the outside of the liposome, either on the bilayer surface or
on the distal end of PEG chains.8,55 Identifying key markers of cancers, such as the folate
receptor that is upregulated in a variety of tumors (e.g. ovary, lung, colon, brain, and breast),
provides a discriminating factor for targeted liposomes to distinguish between diseased and
healthy tissues.85 The binding of these targeting groups to cancerous cells also helps decrease
the retreat of liposomes back into circulation due to high IFP. Drug-loaded nanocarriers, such as
liposomes, are less affected by high IFP in tumors compared to smaller DDSs because of their
larger size.5,72
Nearly all nanoparticle-based therapeutics use the EPR effect as a guiding principle,
except those systems that are targeted to angiogenesis receptors on endothelial cells that are
over-expressed in tumors, thereby destroying the tumor microvasculature (e.g. integrin-αVβ3,
negatively charged phospholipids).1 Therefore, active targeting truly cannot be separated from
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passive targeting (i.e. the EPR effect), because it occurs after passive accumulation has already
happened.5 Active targeting is mainly beneficial for cellular internalization, and moreover, can
compromise the long circulation properties of the liposome when the targeting ligands are
located on the periphery or if the ligands increase unspecific binding to non-target tissue.1,71
Additionally, targeting ligands with high binding affinity may cause an effect known as the
binding site barrier, which impedes further penetration of the liposomes deeper into the tumor.1,71
The binding site barrier phenomenon occurs when targeted liposomes bind tightly to the first line
of cells encountered after extravasation, an event that causes a blockage and a “pile-up,” much
like a wreck on a highway.1 It has been suggested that control over the binding affinity of
targeting moieties to the cell surface receptors may be required in order to prevent binding that is
too strong, such that deeper extravasation of targeted liposomes can be achieved.1,72
1.4.2

Active Triggering
Programmed delivery of liposomal contents is achieved by building a triggerable

functionality into the molecular design of the bilayer, that upon application of the proper
stimulus, either creates leaky interfacial membrane regions, increases the heterogeneity of the
lipid membrane, or causes defects in the bilayer that allows the entrapped contents to be
released.8

The extent of this destabilization can range from simple perturbation of the

permeability of the bilayer or completely disrupting its stability.
Stimuli-responsive liposomal delivery systems can thus be grouped into two general
categories: exogenously- and endogenously-triggered.8 External stimuli include radiation and
temperature, which inherently require localization of the target area prior to treatment and
therefore prevents their use in cases where the diseased site is not necessarily known (e.g.
early-stage and metastatic cancers).8 In addition to this reason, liposome systems that utilize
internal stimuli (i.e. pH and enzymes) to trigger the release of their cargo are more attractive to
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drug delivery, because they offer local control over payload delivery. By using a certain
over-expressed or differentiating characteristic of a disease as an internal stimulus, these
liposomal systems can be programmed to intrinsically trigger upon interacting with that stimulus,
thus achieving site-specific drug delivery.
1.4.2.1 Temperature
The application of heat, or mild hyperthermia, to trigger the release of encapsulated drug
cargo from thermosensitive liposomes affords a unique type of combination therapy. Mild
hyperthermia, which is the local heating of tumor tissue slightly above body temperature (to
~41–43 °C), is selectively detrimental to tumors and can increase the effectiveness of chemo and
radiation therapy.86-87 Tumors are more susceptible to an increase in temperature and experience
enhanced blood flow and vascular permeability versus healthy tissue, further augmenting the
EPR effect.86-87 Mild hyperthermia also selectively interferes with some critical biological
functions of cancer cells, as opposed to normal cells, such as DNA synthesis and repair.86-87 For
these reasons, the coupling of mild hyperthermia with thermosensitive liposomes for drug
delivery is synergistically advantageous and also works to cooperatively minimize damage to
normal tissue.
Two different approaches can be used to trigger drug delivery from thermosensitive
liposomes at tumor sites: (1) interstitial drug release and (2) intravascular drug release.87
Interstitial drug release involves heating tumor tissue after liposome accumulation within the
tumor interstitium has already happened so that the encapsulated drugs are rapidly released in
close proximity to cancerous cells. With intravascular drug release, mild hyperthermia is applied
at the tumor site before the thermosensitive liposomes reach the tumor site; therefore, immediate
drug release occurs upon their arrival in the tumor vasculature.87
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According to Sawant and Torchilin, thermosensitive liposomes can be grouped into two
general categories: (1) those containing temperature-sensitive lipids and (2) those that
incorporate temperature-responsive polymers onto their bilayer surface.3 In both systems, the
thermosensitive liposomes become destabilized by the application of mild hyperthermia.
The main type of temperature-sensitive lipid used in thermosensitive liposomal
formulations

is

1,2–dipalmitoyl–sn–glycero–3–phosphocholine

(DPPC),

and

1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) is commonly added to adjust the main
transition temperature.8,88 Temperature-sensitive lipids undergo a phase transition (gel to liquid)
at a given temperature, called the Tm, which is between 43–45 °C for DPPC/DSPC systems.8,86
When these lipids are formulated into liposomes and heated to their Tm, leaky interfacial regions
or “defects” in the bilayer result and allow encapsulated cargo to be released.
Several variations of this DPPC/DSPC liposome system have been reviewed in the
literature, with emphasis on those discussed by Gerasimov et al.89 and Andresen et al.8 Other
bilayer components were added to impart desired characteristics to the thermosensitive
liposomes, such as stability with cholesterol (Chol),90-92 longer circulation times with
PEG2000-DSPE lipids,90,93-94 and general bilayer adjustments with phosphatidylcholine (PC),90,93
and/or elaidic acid.89,95
Thermosensitive liposomes can also incorporate lysolipids, or pore-forming amphiphiles,
into their bilayers that allow a lower (but still sharp) transition temperature to improve membrane
permeability.8

Needham et al. developed a sterically stabilized liposome composed of

DPPC/DSPE–PEG2000

and

a

lysophospholipid,

1-myristoyl-2-palmitoyl-sn-glycerol-3-

phosphocholine (MPPC).8,96-97 In fact, this type of formulation encapsulating the anticancer
agent Doxorubicin (also known as ThermoDox) has reached Phase-III clinical trials for the
treatment of primary liver cancer.86 Petrov and coworkers have also developed DPPC/DPPG
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liposomes containing lysolipids derived from cholic acid, lysine, and spermine.98-99

Very

recently, Genç et al. developed thermosensitive liposomes composed of DPPC/DPPE
(1,2-dipalmitoylphosphoethanolamine) and lyso-palmitoylphosphatidylcholine (lyso-PPC) that
were used for signal enhancing in an immunosensor, which exemplifies the range of applicability
of these types of liposomes.43
The other genre of thermosensitive liposomes is that which has temperature-sensitive
polymers, or LCST (lower critical solution temperature) polymers, integrated onto their surface.
LCST polymers undergo a temperature-driven transition from a coil to a globular conformation
in aqueous media: these polymers are more hydrophilic (coil) below the LCST and become more
hydrophobic (globular) above the LCST.86 As a result, the bilayer experiences a measure of
mechanical distortion that destabilizes the liposome and facilitates drug release.86 Polymer
derivatives of N-isopropylacrylamide (pNIPAA) that contain hydrophobic moieties as anchors
are used most often, and the LCST of pNIPAA is adjusted by copolymerization.86,100 For
example, Hayashi and Kono copolymerized pNIPAA and octadecylacrylate to generate a
thermally-sensitive copolymer that was incorporated into dioleoylphosphatidylethanolamine
(DOPE) liposomes, which were stable below 30 °C but rapidly released their contents at
40 °C.101

pNIPAA has also been copolymerized with propylacrylic acid, the latter of

which is pH-responsive, thus resulting in a dual-responsive system.102 As an alternative to
non-biodegradable pNIPAA, Paasonen et al. used poly(hydroxypropylmethacrylate) a.k.a.
pHPMA.103 Another LCST polymer, poly(2-(2-ethoxy)ethoxyethyl vinyl ether-block-octadecyl
vinyl ether) or EOEOVE-block-ODVE, has an LCST around 40 °C and has been incorporated
into PEGylated liposomes by Kono and coworkers.104-105
A convenient segue into the following section about photosensitive liposomes is to
briefly discuss photothermal triggering, a method that combines both heat and light stimuli for
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liposome opening.

Photothermal triggering takes advantage of the heat emitted from

light-absorbing chromophores during their decay from an excited state to the ground state.106 In
other words, heat generated from irradiation by light is harnessed to effect bilayer destabilization
in liposomes.

The key component in most photothermally-triggered liposomes is gold

nanoparticles or hollow gold nanoshells, both of which are responsible for translating light
absorption into a highly-localized hyperthermal effect.

Paasonen et al. have developed

photosensitive liposomes composed of DPPC/DSPC with gold nanoparticles embedded in the
bilayer.103,107 Similarly, Wu and coworkers used hollow gold nanoshells in their PEGylated,
DPPC-based liposomes that are destabilized with 800-nm, near-infrared light.108
1.4.2.2 Light
Using light as a stimulus for liposome opening is advantageous from the viewpoint that it
offers a broad range of adjustable parameters (e.g. wavelength, intensity, duration) with which to
tune the system.89,106 However, one of the limiting factors with this triggering method is that
some wavelengths of light may not be suitable for drug delivery applications because of
hazardous side effects from prolonged exposure and/or interfering chromophores present in the
body.89 According to Wang et al., near-infrared light may be the optimum wavelength to use for
phototriggering liposomal drug delivery systems.109

Nonetheless, several comprehensive

reviews have been written over the years about photoactivated liposomes that destabilize as a
result of light-induced polymerization, fragmentation, or isomerization.89,106,109
Photopolymerizable liposomes are composed of photosensitive lipids that form a
cross-linked lipid network upon exposure to UV light; the crosslinking event creates defects in
the bilayer and subsequent release of the carried cargo.109 The overwhelming majority of these
systems

contain

1,2-bis[10-(2’,4’-hexadienoyloxy)decanoyl]-sn-glycero-3-phosphocholine

(bis-SorbPc), a photosensitive lipid that is the key player in the triggerable mechanism.8,109 For
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example,

Bondurant

et

al.

developed

photopolymerizable

liposomes

composed

of

PEG2000-DOPE/Chol/DOPC/bis-SorbPC, and later it was concluded that the permeability of
these liposomes increased 28,000-fold upon UV exposure.110-112 Lamparski et al. determined
that the rate of contents release depends on the extent of bis-SorbPC polymerization (and other
factors) based on experiments with their DOPE/bis-SorbPC photosensitive liposomes.109 With
the addition of a green light absorbing dye, distearoyl indocarbocyanine (DiIC), Mueller et al.
were able to make their PEG2000-DOPE/bis-SorbPC/DOPC liposomes sensitive to
both UV and visible light.109,113

More recently, a diacetylenic phospholipid called

1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC) was incorporated into
DPPC liposomes to induce rupture when irradiated with 254-nm light.114

This new

photopolymerizable component, DC8,9PC, was also included in the formulation of
PEG2000-DSPE liposomes.115
Photofragmentation, or photodeprotection, involves the light-induced cleavage of a
bilayer-stabilizing group that results in liposomal contents release. A prime example of this type
of system is liposomes that contain 6-nitroveratryloxycarbonylated DOPE (NVOC-DOPE) lipids
whose carbamate bonds undergo photolysis when irradiated with > 300-nm light to liberate
carbon dioxide, 3,4-dimethoxy-2-nitrosobenzaldehyde, and DOPE.8,106,109,116

NVOC-DOPE

lipids have also been formulated into liposomes with egg phosphatidylethanolamine (EPE).109,116
Chandra et al. incorporated a photosensitive o-nitrobenzyl-based lipid into DSPC liposomes,117
while Eastoe et al. modified cetyltrimethylammonium bromide (CTAB) liposomes with an
anionic photolyzable surfactant, sodium 4-hexylphenylazosulfonate (C6PAS), that breaks down
into alkane hexylbenzene and 4-hexylphenol (a weak surfactant) upon exposure to UV
radiation.118 Very recently, Bonnet and coworkers mixed a ruthenium (Ru) complex with either
dimyristoylphophatidylglycerol (DMPG) or dimyristoylphophatidylcholine (DMPC) to form
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liposomes that undergo photofragmentation using 452-nm visible light.119 Upon irradiation, the
Ru complex is broken down and forms a cationic aqueous complex that strongly interacts with
the lipid membrane, causing partial liposome fusion and destabilization.119
A pseudo-subset of photofragmentation is photooxidative cleavage, which is
characterized by an increase in membrane permeability due to the oxidative cleavage of
plasmenylcholine from single-chain surfactants upon near-infrared light (630–820 nm)
exposure.106 Plasmenylcholines are naturally occurring vinyl ether lipids that help protect animal
cells from singlet-oxygen species caused by UV light.89,109

Upon photooxidation, the

plasmalogen vinyl ether linkage liberates single-chain surfactants (lysolipids and fatty aldehydes)
that cause a lamellar-to-hexagonal phase change in the bilayer.106 A key component in these
photooxidative liposomal formulations is a photosensitizer (e.g. zinc phthalocyanine, tin
oxtabutoxyphthalocyanine, bacteriochlorophyll) that harnesses the near-infrared radiation and
oxygen to produce reactive-oxygen species.106,120

Thompson et al. found that when

bacteriochlorophyll

1-alk-1’-enyl-2-palmitoyl-sn-glycero-3-

a

was

incorporated

into

phosphocholine (PlasPPC)/DPPC liposomes, 100% of the encapsulated cargo (calcein) was
released in less than 20 minutes.109

The single-chain surfactant products that result from

photooxidation also laterally diffuse within the bilayer, separating into domains that create
defects or pores and cause liposomal fusion and destabilization.109

To amplify the initial

photoresponse, Wymer et al. coupled the release of Ca2+ from photooxidized diplasmalogen
liposomes with PLA2 (a calcium-dependent enzyme) to then trigger the subsequent
destabilization of another population of calcein-containing liposomes in a cascade-type
mechanism.10

The Ca2+-loaded liposomes were composed of a synthetic diplasmalogen

(1,2-di-o-hexadec-1’(Z)-enyl-sn-glyceryl-2-phosphocholine, (DPPlsCho)), dihydrocholesterol
(DHC),

and

1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
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(DPPE)

conjugated

to

PEG5000.8,109 The calcein-containing liposomes were conventional formulations of DPPC that
ruptured upon calcium-activation of PLA2 and subsequent PLA2-induced destabilization of the
DPPC bilayer.8,109
All of the phototriggering mechanisms discussed thus far are irreversible in nature and
result in the rapid release of liposomal payloads. Therefore, to exert more control over these
types of systems, liposomes that destabilize upon photoisomerization may be desirable to
effectively “gate” the containment/release of encapsulated contents.
photoisomerizable

liposomes

are

based

on

azobenzene

The majority of

derivatives

[1,2-(4-n-butylphenyl)azo-4-(γ-phenylbutyroyl)-glycero-3-phosphocholine]

or

such

as

Bis-Azo

PC,

which is a photochromic lipid that undergoes cis-trans isomerization upon irradiation with
near-UV light.8,106,121-122 More specifically, the thermodynamically stable trans form of Bis-Azo
PC allows tight packing of the lipid in the bilayer; however, after photoisomerization to the
bulky cis-isomer, the bilayer becomes disrupted and more permeable to release the entrapped
cargo.106,109

Bisby et al. studied Bis-Azo PC/DPPC liposomes and found that addition of

cholesterol affects the wavelength range over which these liposomes can be phototriggered.121
The trans-to-cis isomerization is achieved through irradiation with 320-nm UV light, and the
cis-to-trans reversal is obtained with 430-nm visible light or by heating, thus demonstrating the
reversibility of this system.109 Impressively, Morgan et al. showed that Bis-Azo PC/DPPC
liposomes completely released encapsulated calcein within milliseconds of phototriggering.109
Recently, a negatively-charged alkyl surfactant was prepared into liposomes with a
positively-charged azobenzene-conjugated surfactant to produce cationic liposomes (50–200 nm
in diameter) that rupture upon exposure to UV light for application in gene delivery.123
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1.4.2.3 Acid
The lower pH conditions of tumors is due to the accumulation of lactic acid and ATP
hydrolysis products which result from elevated metabolic processes of cancerous cells under
hypoxic conditions.3,124 The original and much less viable strategy of utilizing the general acidic
microenvironment of tumors to trigger pH-sensitive liposomes was rather unsuccessful: the
tumor interstitium is only about pH 6.5 at the lowest, which is not very different from
physiological pH 7.1–7.4 and makes it difficult to design pH-triggerable liposomes that remain
stable in the blood but then destabilize in the tumor.3,8,124 But, it has been reported that the pH of
tumors can be artificially lowered even more (about 1 pH unit lower) by injecting glucose into
the bloodstream, which increases the production of lactic acid.71
A more practical approach is to utilize the acidic endosomal environment (pH 5.5) to
trigger the release of the drug cargo from the liposomes after internalization by the endosomes.
Moreover, with the popularity of active targeting, it should be considered that the fate of
liposomes with receptor-targeted ligands is also endocytotic uptake. While endocytosis can
occur in the absence or presence of ligand, it is facilitated by the presence of cationic ligands,
and internalization is highly dependent on the size of the DDS (ideally between 100–200 nm).55
Eventually, endocytosis results in lysosomal degradation (pH 4.5) and destruction of the
liposomes and their precious drug cargo.8,71 (However, it should be noted that some drugs are
quite stable in endosomes/lysosomes such as anthracyclines and doxorubicin.8)

Thus, this

strategy has resulted in the use of fusogenic liposomes whose lipids undergo a phase transition,
from a lamellar bilayer (Lα) to inverted hexagonal (HII) micelles, and are able to fuse with the
endosomal membrane to deliver drugs into the cytoplasm of cancerous cells.8 Consequently,
fusogenic lipids (e.g. DOPE) have become a benchmark in the design of pH-sensitive liposomal
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formulations, which also include any combination of stabilizing lipids, polymers, amphiphilic
molecules, and/or targeting ligands (e.g. antibodies, peptides).
Unfortunately, the benefits that active targeting ligands provide liposomes (especially
site-specific direction and internalization into cancerous cells) have been challenging to reap
because of the necessary inclusion of a PEG-protected liposomal periphery. The PEGylated
exterior may hamper the fusogenic potential of these liposomes by sterically preventing the
contact-driven fusion and destabilization events, and also decrease liposome uptake into cells.8,71
Furthermore, the protective PEG corona also shields the buried targeting moieties (anchored on
the bilayer surface) from their respective tumor cell-specific receptors, thus reducing cell
internalization.8 In response, targeting ligands were attached to the distal end of PEG chains for
better ligand-receptor interaction; however, some research has shown that this approach
compromises the protective cover of the PEG corona and increases liposome immunogenicity.3,8
Due to these types of challenges, the evolution of pH-responsive liposomes has lead to highly
complex, multifunctional systems (e.g. detachable PEG, cell-penetrating moiety).3
pH-sensitive liposomes are most commonly composed of DOPE and weakly acidic
amphiphiles, such as oleic acid or cholesteryl hemisuccinate (CHEMS).3 As a case in point, the
first pH-sensitive liposomes were composed of oleic acid and DOPE whose bilayer
destabilization occurred at pH 6.5, resulting in earlier drug release outside of the cytoplasm or at
the onset of endocytosis.124-128 To delay drug delivery, a DOPE and CHEMS mixture can be
prepared into liposomes so that the bilayer permeability does not increase until the lysosomes are
reached at around pH 5.5.124,129-130 Liposomes composed of DOPE/CHEMS were eventually
modified with the addition of a hydrophilic polymer, such as mPEG2000-DSPE, to increase their
circulation time in vivo.3,131-133

Another DOPE/CHEMS liposome system incorporated an
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antibody (EGFR) to the distal tip of the PEG-lipid conjugate,134 while other liposomes have used
folate and transferrin as active targeting ligands.3,135-137
As briefly alluded to earlier, the triggered loss of the PEG coating after reaching the
tumor would be highly advantageous, because the obstacles/problems presented by
sterically-stabilized liposomes could be overcome if the PEG was detachable.

Szoka and

coworkers138-139 present a good example of an efficient sheddable-PEG liposome system that is
composed of DOPE and distearoyl glycerol conjugated to detachable PEG through a diorthoester
bond, which undergoes rapid hydrolysis around pH 5.5.3

Some researchers believe that

exogenous administration of cysteine to cleave thiol-conjuated PEG is more advantageous than
mild acidic pH or matrix metalloproteinase triggers, because it allows external and precise
control over the shedding of PEG.85,140 Blending various pH-sensitive lipids into liposomal
formulations and even conjugating lipids to different molecular functionalities provides a way to
tune or adjust the destabilization behavior of these triggerable liposomes to release their contents
at an optimal pH range.124 While pH-sensitive liposomes, and liposomes in general, offer this
rather simplistic method of modification (i.e. easily incorporate different lipids/modifiers), it can
often involve major synthetic overhauls or brand new synthetic routes.

In summary, the

evolution of pH-sensitive liposomes has lead to highly complex, multifunctional systems whose
behavior has not yet been well characterized, especially in vivo.3
1.5

Enzyme-activated Liposomes

1.5.1

Preceding Prodrug Examples
It is widely known that chemotherapeutic agents wreak havoc on healthy tissue due to

their poor selectivity, and their narrow therapeutic index and propensity to induce multidrug
resistance with prolonged treatments add to the challenges surrounding the administration of
these toxic drugs.9 For decades now, scientists have been developing an array of enzymatically
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triggered prodrug formulations to improve the bioactivation of these masked anticancer agents at
tumor sites and to address the other problems cited above.
Prodrugs and bioactivatable drugs are inactive (or less potent) compounds that require
transformation in vivo to their active metabolite in order to exhibit its pharmacological effects.141
Both endogenous and nonendogenous enzymes have been used to activate produgs, and a large
number of these systems were discussed in an extensive 2004 review by Rooseboom et al.9 As
outlined in this document, the endogenous enzymes are categorized into four distinct classes
according to the International Union of Pure and Applied Chemistry (IUPAC): Class 1 are the
oxidoreductases, Class 2 are the transferases, Class 3 are the hydrolases, and Class 4 are the
lysases. Even though only a few different enzymatically-triggered liposome delivery systems are
reported in the literature, the precedent set forth by prodrug development has pioneered the path
for this young field.
Alkaline phosphatase is a widely specific enzyme that is found in serum and bound to
cellular membranes, catalyzing the hydrolysis of phosphoric esters to alcohols and phosphates.9
The abundance and wide distribution of alkaline phosphatase in living organisms limits its use to
locally activate prodrugs, except when uses in conjunction with (antibody–, gene–, or virus–)
directed enzyme prodrug therapies.9

S-2-(3-Aminopropylamino)-ethylphosphorothioic acid

(Amifostine) is a clinically used anticancer prodrug that undergoes bioactivation via
dephosphorylation by alkaline phosphatase.9
Matrix metalloproteinase–2 and –9 (MMP–2, MMP–9) are extracellar enzymes that are
over-expressed in a variety of cancers and break peptide bonds in nonterminal amino acids.1,142
Kline et al. synthesized both peptidic and sequence-similar peptidomimetics enzyme prodrugs to
determine the best substrate(s) for the proteinases.143

One issue with the development of

prodrugs is retention of the drug’s activity after bioactivation. For example, prodrugs containing
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the peptide sequence acetyl L-prolyl-L-leucyl-glycyl-L-leucine (AcProLeuGlyLeu) would
strongly resemble the natural substrates of MMPs; however, a portion of the leucine residue
remains on the drug after cleavage by the enzyme.143 Depending on the drug, activity can be lost
lowering its therapeutic efficacy. Fortunately, Doxorubicin tolerates conjugation with leucine,
and in fact, L-leucyldoxorubicin (LeuDox) shows strong antitumor activity both in vitro and in
vivo.143 As a result, doxorubicin and several other drugs were formulated into prodrugs for
MMP–2 and –9. Similarly, Chau et al. prepared new dextran-peptide-methotrexate conjugates to
deliver chemotherapeutic agents selectively to tumor sites by targeting MMP–2 and –9.144
Due to their wide distribution in the human body, carboxylesterases are mainly used in
antibody– or gene–directed enzyme prodrug therapies.9 Carboxylesterases aid in the conversion
of carboxylic esters to alcohols and carboxylic acids, but they are also capable of hydrolyzing
amides, thioesters, phosphoric acid esters, and acid anhydrides.9 Paclitaxel-2-ethylcarbonate is
an example of a prodrug that has been converted to its cytotoxic parent drug, Paclitaxel (Taxol),
by carboxylesterase present in rat serum.9 It seems relevant to also comment on the role of
esterases in prodrug activation and the stability of prodrug ester bonds in vivo. The ubiquity of
esterases in the body is undisputed, and the incomplete catalog of their whereabouts and the
various types of esterases just compounds the problem of being able to fully exploit their use as
bioactivating agents.9,145 Consequently, the design of esterase-sensitive prodrugs (i.e. those
containing ester bonds) seems pointless, especially because of the added concern as to whether
ester bonds are stable in biological systems. A time-tested example of an ester bond persisting in
a biological environment, however, is the prodrug acetylsalicylic acid or asprin.145 Another
popular use of esterases, especially in the realm of nanoparticle-based drug delivery is to
facilitate the removal of protective PEG chains from these delivery vehicles. For example, Xu et
al. modified pH-sensitive liposomes with PEG-lipid derivatives whose ester bonds were cleaved
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upon esterase action, thus providing a way to selectively shed the PEG coating in order to
achieve efficient contents release and long circulation times, simultaneously.146
In conclusion, the variety and myriad of enzymes that have been utilized to activate
prodrugs proves their importance to the future of triggerable liposome delivery agents, not to
mention other nanoparticle-based delivery systems as well. Elastase17,147-148 and phospholipases
C8,18,149 and A21,8,13,150-151 are other enzymes being explored for liposomal activation. As more
information is learned about the metabolism and microenvironment of cancer, the more these
tumor-specific (endogenous) enzymes can be employed in liposome drug delivery and the further
this field with go.
1.5.2

Secretory Phospholipase A2 (sPLA2)
Enzyme overexpression in the extracellular environment of tumors is already well

understood, clearly evidenced by the bounty of endogenous enzymes used to activate prodrugs.
As pointed out by Andresen et al., all of the successful enzyme-triggered liposome delivery
systems have utilized secretory enzymes that induce extracellular drug release.1 However, in this
same review article, it is also made clear that other intracellular enzymes may be upregulated in
cancer cells (versus healthy cells) and could potentially be targeted for drug release in the
future.1

In fact, with increasing knowledge about the intricacies of tumor biology (i.e.

intracellular composition) and the development of multifunctional liposome carriers, using
intracellular enzymes to trigger drug release will undoubtedly be realized. To date, though, two
of the main enzymes reported in the literature that initiate liposomal drug release extracellularly
are secretory phospholipase A2 (sPLA2) and extracellular matrix metalloproteinases (MMPs), the
latter being discussed in a later section.
Part of the phospholipase A2 superfamily, sPLA2 belongs to a subgroup of small secretory
enzymes that range in size from 14–19 kDa and require millimolar concentrations of Ca2+ for
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activation.1,152 The function of these enzymes is to catalyze the hydrolysis of the sn–2 ester bond
in glycerophospholipids, producing free fatty acids and lysophospholipids.1,152

sPLA2 is

over-expressed “many-fold”150 in various cancers such as prostate, breast, and pancreatic, with
type IIA (sPLA2–IIA) being the most studied and the highest concentrated type in cancerous
tissue.1,152 While the presence and upregulation of sPLA2 in tumors is undisputed, its role in the
development of human cancer is still being elucidated; although, it has been suggested that
sPLA2 over-expression is an indirect response to stimulation of inflammatory cytokines.152-153
More importantly, sPLA2–IIA has been linked to the increased aggressiveness of tumors.153
Interestingly, aggregated phospholipids (e.g. liposomes and micelles) are more
susceptible to sPLA2–catalyzed hydrolysis versus lipid monomers, which is highly dependent on
lipid composition, morphology/arrangement, and especially membrane charge.1,153 sPLA2–IIA is
highly specific towards anionic phospholipid membranes, compared to neutral membranes
composed of zwitterionic lipids (e.g. phosphocholines) which induce virtually no enzymatic
action from sPLA2–IIA.1,153 The large concentration of cationic residues on the sPLA2–IIA
surface is responsible for this enhanced specificity towards anionic membranes.153 Fortunately,
the surface of unperturbed, native mammalian cells is composed of mostly neutral lipids such as
sphingomyelin, phosphatidylcholines, and cholesterol, which consequently makes healthy cells
poor substrates for sPLA2–IIA–catalyzed degradation.153
In terms of developing sPLA2–activated liposome delivery agents, lipids of optimal
charge and composition should be chosen and the liposome prepared in such a way as to
maximize sPLA2 activity. The necessary inclusion of protective PEG chains into liposomal
formulations, for increased in vivo circulation times, actually enhances the activity of sPLA2
toward these sterically stabilized liposomes.1 Conjugation of PEG to the positively charged
amine of the phospholipid neutralizes the charge, resulting in a PEG-lipid conjugate with a net
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negative charge from the phosphate group which promotes sPLA2 interaction.1 Moreover, the
protective PEG coating does not seem to hinder the approach of sPLA2 enzymes to the liposome
surface; on the contrary, these enzymes appear to readily penetrate the PEG corona and
successfully hydrolyze the anionic lipids.1
sPLA2–activated liposomes that have been reported in the literature are either traditional
drug-loaded formulations or composed of prodrug conjugates wherein the drug is incorporated
into the phospholipid backbone and/or is the cytotoxic ether lipid component that results from
sPLA2

hydrolysis.

After

activation

by

sPLA2,

traditional

drug-loaded

DSPC/DSPG/DSPE-PEG2000 liposomes expel bilayer-destabilizing lysolipids and fatty acids
that enhance the permeability of nearby cellular membranes and facilitate intracellular uptake of
the released drug cargo.13 This same idea was applied to a more complex, cascade-type system
where DPPC liposomes were destabilized by PLA2 after another population of photosensitive
liposomes released Ca2+ ions upon irradiation with 800-nm light (see discussion of
light-triggered liposomes).1,8,10,109
Anticancer ether lipids (AELs) are a class of anticancer drugs that slow the progression of
tumor growth without inducing myelosuppression or mutagenic effects.13 Prodrug versions of
AELs, referred to as “proAELs” (e.g. proAEL–PC, proAEL–PG), have been incorporated into
the bilayer of liposomes and only reveal their cytotoxic nature after activation by sPLA2.13 A
proAEL thio-ester variant has also been reported.154 To further increase the anticancer punch of
this treatment type, double proAELs have also been synthesized and prepared into liposomes.13
In double proAELs, the sn–2 fatty acid chain is replaced with a drug (i.e. retinoids,11,13
prostaglandins,13 chlorambucil12) so that the free AEL and drug are released after sPLA2
hydrolysis.13 Cytotoxic retinoids have also been prepared into liposomes for sPLA2-triggered
release.11 Composed of a cytotoxic lysolipid (AEL-like) conjugated to a retinoid (e.g. all-trans
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retinoic acid, ATRA), these cytotoxic retinoid-based liposomes represent another type of “double
dose” approach, much like the double proAELs.11

Liposomes composed of synthetic

capsaicin-lipids undergo destabilization by a unique sPLA2–initiated intramolecular cyclization
reaction that releases free capsaicin, an anticancer agent, from the phospholipid backbone.155 In
this particular formulation, the sn–1 fatty acid position is substituted with capsaicin, and
interestingly, the authors also report that these novel phospholipids spontaneously formed small
unilamellar vesicles (liposomes) upon dispersion in a buffer with no sonication or extrusion
needed.155
1.5.3

Matrix Metalloproteinase (MMP)
MMPs are essential for malignant tumor growth, invasion, metastasis, and angiogenensis,

as these zinc-dependent endopeptidases are responsible for the degradation of extracellular
matrix components, a process necessary for cancer development and progression.1,142,156 While
transmembrane MMPs exist, only extracellular MMPs (i.e. MMP–2 and MMP–9) have been
exploited as endogenous stimuli for triggering liposomes. MMP–2 (Gelatinase A) and MMP–9
(Gelatinase B) are over-expressed in a variety of cancers, such as brain, breast, cervical,
colorectal, and many more.1,143,156 These gelatinases are responsible for the degradation of
basement membranes by catalyzing the hydrolysis of peptide bonds in nontermial amino acids.142
The

general

amino

acid

substrate

sequence

recognized
143

L-prolyl-L-leucyl-glycyl-L-leucine (AcProLeuGlyLeu).

by

MMPs

is

acetyl

Like PEGylated liposomes activated

by sPLA2, the much larger MMP–2 (72 kDa) and MMP–9 (92 kDa) enzymes can also penetrate
the protective PEG layer and catalyze the hydrolysis of peptide substrates on the bilayer surface.1
Once again, this finding validates the fact that enzymes, in general, must be able to access and
effect their transformations on substrates hidden below the PEG corona.
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Even though PEG chains do not interfere with accessibility of the enzyme to the bilayer
surface, they may cause reduced cellular uptake of liposomes and/or hamper the release of
encapsulated cargo, particularly from fusogenic liposomes that require bilayer fusion to effect
destabilization and rupture. To this end, several systems have been reported that utilize MMP–2
to facilitate the timely removal of PEG coatings from stealth liposomes. Terada et al. coupled
DOPE to a PEGylated MMP–2-cleavable peptide, and the lipid was prepared into liposomes with
galactose-terminated PEG-DOPE lipids to selectively target hepatocellular carcinoma (HCC).23
Their idea was that MMP–2 would facilitate dePEGylation of these liposomes once they reached
HCC cells to achieve efficient cellular uptake. Similarly, Hatakeyama et al. developed a system
composed of a PEGylated MMP–2 cleavable peptide coupled to DOPE that was blended into
liposomes with free DOPE.157

This modified multifunctional envelope-type nanodevice

(MEND) was prepared in order to transport a condensed DNA/polycation complex for systemic
gene delivery for cancer therapy.

A few years later, this system was improved upon by

incorporating a pH-sensitive fusogenic GALA peptide (GALA/Chol-anchored) to control
intracellular trafficking and to improve gene silencing both in vitro and in vivo.158
In 2005, the first report of MMP-triggered liposomes was published using MMP–9 to
degrade lipopeptides that were integrated into DSPC liposomes, resulting in destabilization and
subsequent cargo delivery.14 These lipopeptides were composed triple helical collagen-mimetic
peptides coupled to stearic acid and made up about 10% of the liposomal bilayer.14 Later, some
mechanistic studies of this system were performed, in which various lipopeptides
(containing

either

stearic,

oleic,

or

palmitic

acid)

were

mixed

with

POPC

(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), DOPC, or DSPC.15 Finally, in 2009, an
optimum formulation of 30% lipopeptide and 70% POPC liposomes was tested with HT-29
(colorectal adenocarcinoma cells) and MCF-7 (breast adenocarcinoma cells), to find that the
38

latter cell line triggered contents from these liposomes because of its sufficient concentration of
MMP–9.16
1.6

A Redox-active Liposome Delivery System

1.6.1

Rationale for Quinone-Lipid Design
Each individual component of the quinone-dioleoylphosphatidylethanolamine (Q-DOPE)

lipid serves a specific purpose that enables the overall structure of the liposome to function as a
viable drug delivery vehicle. Phosphatidylethanolamine (PE) lipids provide the crucial lamellarto-inverted hexagonal (Lα-HII) phase transition needed to sufficiently destabilize the lipid bilayer
and release the liposome contents into the surrounding environment.6 The mechanism by which
this phase transition occurs is two-fold: First, disconnection between the liposome, or Lα phase,
stabilizer (quinone) and the PE lipid reintroduces electrostatic interactions between the
positively-charged amine and the negatively-charged phosphate group of the free PE; then, any
contact between these now fusogenic lipids and another membrane surface (i.e. fusogenic or
cellular) induces destabilization of the bilayer.159 Electrostatic attraction between the oppositelycharged amine and phosphate groups decreases the area of the PE polar heads, resulting in coneshaped PE lipids that reorganize from a bilayer into reverse micelles.6
As these liposomes undergo destabilization, the removal of water from their surfaces is
an important step in the membrane fusion process. The first instance of DOPE dehydration
occurs upon cleavage of the quinone stabilizer from the DOPE lipid,160-161 which is hypothesized
to correspond to the “contraction” or “lag time” that was observed in the calcein release
experiments (see Chapter 4).

Hydration repulsive forces prevent the close approach of

liposomes; therefore, removal of water facilitates the ability of two or more liposomes to
establish a zone of contact and finally achieve intermembrane interaction.160-161 The other key
dehydration step occurs during formation of the HII-phase, reverse micelles that organize into
39

tube-like structures, requiring highly efficient packing—which precludes the presence of a large
amount of water.160-161
Perhaps the most important component of the active-triggering mechanism, the
redox-active quinone moiety serves two primary functions: (1) it stabilizes the liposome (or Lα
phase) by inhibiting the DOPE phase transition from Lα to HII until reductive activation and (2) it
provides a palette on which to add various functional groups that will tune the specificity and
rate of liposome opening. Furthermore, the biocompatibility of quinones has already been
established with the presence of Coenzyme Q, Plastoquinone, Ubiquinones, Vitamin K, and
other quinones in biological systems.162-163 For example, Coenzyme Q is known to function as a
redox constituent in the mitochondrial oxidative phosphorylation system, transporting electrons
between Complex I/II and Complex III.162
Precedents for using quinones, or more specifically trimethyl lock-based benzoquinone
derivatives, as protecting groups has been reported in the literature for prodrugs35,164-166 and in
dendritic systems38,167 from our laboratory. Moreover, research has shown that murine NQO1
reduces various quinones at rates dependent on the electronic structure of the quinone. The
quinone reduction potential relates to the rate of both reduction168-169 and lactonization26,28
providing a useful measure for destabilization.

The quinone functionalities (ranging from

electron-donating to electron-withdrawing) will also allow the liposomes to be tuned to different
potentials in order to prevent cross-reactivity between our liposomes and other interfering
enzymes and redox agents, so as to stave off premature release.
1.6.2 Mechanism of Destabilization
The active release mechanism works via a disconnection between the phospholipid and
liposome stabilizer and causes instability in the bilayer and subsequent delivery of the liposome
contents.17
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Our redox-triggered liposome delivery vehicles are composed of a redox-active quinone
liposome stabilizer and a DOPE phospholipid, which disconnect after reduction via NQO1, a
tumor-associated reductase.

Scheme 1.1. Cartoon illustration depicting the fundamental event involved in the active release
mechanism of our redox-active liposomes.
In our system, the mechanism by which this Lα-HII phase transition occurs is a two-step process:
First, the quinone undergoes a 2-electron reduction to the hydroquinone, which then initiates a
spontaneous intramolecular cyclization/elimination that expels lactone molecules and free DOPE
in the form of fusogenic liposomes (Scheme 1.1) The “trialkyl lock,” which is located on the
right side of the quinone (Y = CH3, R3 = CH3), accelerates cyclization to the lactone through the
“gem-disubstituent effect”170 and conformational restriction known as “stereopopulation
control.”26-37 When the trialkyl lock is absent, the rate of lactonization is 103 times slower.33
However, Winans and Wilcox argued that conventional steric strain relief is the predominant
factor for catalyzing lactonization.32

From empirical force field model calculations, they

concluded that qualitatively at least 70% of the total free energy steric effect in this type of
system comes from conventional steric strain relief, compared to the contribution from
stereopopulation control (entropic factor).32
According to Winans and Wilcox, it is clear that Milstein and Cohen credited
stereopopulation control with too much influence over the rate enhancement and grossly
underestimated the effect of conventional steric strain relief.32 Nonetheless, Jung and Piizzi
discuss examples of several prodrug, pro-prodrug, and PEGylated prodrug formulations that
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have been developed based on
o a trimetthyl lockedd system.170

Upon bioactivation, the

intramoleecular cyclizzation reactioon, which reesults in cleaavage and ellimination off the free druug, is
facilitated by the trim
methyl lock at
a enhanced rates on the order of 105–1011.170

Scheme 1.2. Illustraation showinng the destaabilization mechanism
m
o our Q-DO
of
OPE liposom
mes at
the moleecular-scale. After reduuction and liberation
l
off the lactonee, the resultiing DOPE lipids
l
create fuusogenic “po
ockets” or siites on the bilayer
b
surfaace, making the liposom
mes susceptibble to
contact-ddriven rupturre due to thee Lα-to-HII phhase transitioon of DOPE
E.
W
While
the un
nderlying forrces responssible for thee joining toggether of tw
wo apposing lipid
bilayers are still unrresolved, this phenomennon is well-kknown as a vital processs in biologyy and
cellular ffunctions.171 Liposomee fusion occurs in bilayyer membrannes wherein a portion of
o the
lipid com
mposition is fusogenic and
a able to form non-laamellar struuctures. Oncce the liposomes
become fusogenic, any
a contact or collisionn with anotther fusogennic liposomee or even a cell
membranne will resullt in destabillization and rupture of thhe bilayer caaused by thee phase transsition
of DOPE
E, releasing the
t entrappeed contents innto the surroounding envvironment. Depending
D
o the
on
lipid com
mposition, this generaalized proceess can takee a few different rouutes: the unnified
(conjoineed) membraane can either remaiin stable long
l
enough to form
m intermembbrane
1
intermeddiates (IMIs), have content mixing inn its interior, or completeely destabilizze via lysis.172
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1.6.3

NAD(P)H:quinone Acceptor Oxidoreductase (NQO1)
NAD(P)H:quinone acceptor oxidoreductase type 1 (NQO1) is a 62 kDa detoxifying,

flavoenzyme that catalyzes the 2-electron reduction of quinones to hydroquinones, which
protects animal cells from harmful and carcinogenic effects of free radicals resulting from
one-electron reductions.24-25,173-175 This type 1 form is the predominate type of this enzyme in
humans.9 While human NQO1 (hNQO1) is mainly present in the cytosol of cells, it is also
located in the nucleus.176 Nakamura and Hayashi reported that NQO1 is even present in the
plasma membrane of rat liver cells,177 which brings much hope to finding the presence of
extracellular or membrane-bound hNQO1. hNQO1 is over-expressed in tumors, such as those of
the liver (4– to 19–fold), lungs (12– to 18–fold), breast (3–fold), and gastrointestinal tract (colon,
3– to 4–fold), which makes this reductase enzyme an attractive facilitator for activating
chemotherapeutic agents.9,24-25,173-174

The crystal structure of hNQO1 reveals four subunits

(tetramer), each containing a noncovalently bound FAD cofactor molecule, and arranged as a
pair of two homodimers.24-25,173-174 The active site, which is located at the interface of each
dimer, is highly flexible and can accommodate various quinone substrates into its 360 Å3
pocket.24-25,163 NAD(P)H also cycles in and out of this active binding site but must be released
before the (quinone) substrate can bind.173 The “ping pong” mechanism of this two-electron
reduction involves direct hydride transfers from NAD(P)H to FAD and then from FADH2 to the
quinone.24-25,173-174
Mitomycin C and its aziridinylquinone analogues, Apaziquone (EO9) and Diaziquone
(AZQ), are quinone-based bioreductive drugs activated by NQO1 that exhibit antitumor activity
primarily by inducing DNA alkylation.9,163,165 The wide variety of quinone substrates that NQO1
can metabolize is impressive, as NQO1 can also activate other quinoidal bioreductive drugs (e.g.
Streptonigrin, Menadione) and even Tirapazamine and CB1954, which are nonquinoidal
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bioreductive drugs.9 In addition to quinones, quinone epoxides, aromatic nitro and nitroso
compounds, azo dyes, and chromium VI are also known substrates of NQO1.163

Quinones can

also be used in the formulation of prodrugs as promoieties to release cytotoxic agents.
Indolequinones have been coupled to antitumor drugs such as camptothecin and phosphoramide
mustard.165 Benzoquinone-derived prodrugs that contain the TML have been used to facilitate
the release of melphalan, semaxanib (SU5416), and 4-aminophenyl nitrogen mustard.35,165 This
particular type of promoiety is the same “protecting group” or “liposome stabilizer” used in the
design of our redox-active liposome delivery vehicles.

Finally, naphthoquinone- and

benzoimidazolequinone-type promoieties have been used to transport phosphoramide mustard,
which is then released by rearrangement of the imidazole electrons and via quinone-methide
elimination, respectively, after bioreduction.165 For example, Flader et al. synthesized a series of
(naptho– and benzimidazole–) quinone phosphorodiamidates that were designed to be activated
by NQO1 to release a cytotoxic phosphoramide mustard alkylating agent for DNA
crosslinking.178-179 Therefore, the extensive literature about NQO1, covering everything from
NQO1 overexpression in tumors to the prodrugs developed for NQO1-bioactivation, has paved
the way for the development of our NQO1-triggered liposomal delivery system.
1.7
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CHAPTER 2
SYNTHESIS AND CHARACTERIZATION OF ALL HYDROQUINONE– AND
QUINONE–BASED COMPOUNDS
2.1

Syntheses

2.1.1

Materials and General Considerations
All reagents were purchased from Sigma-Aldrich or TCI America and used as received.

Compounds 1a&b, 1d, 1h, 2a–d, and 2g are commercially available. Column chromatography
was performed using either silica gel purchased from Sigma-Aldrich (pore size 60 Å, 200–400
mesh) or with a Biotage FlashMaster Personal Chromatography System with SPE ISOLUTE
FLASH Silica II disposable columns (pore size 60 Å, particle diameter 40–63 µm).

1

H NMR

spectra were recorded at either 300 or 400 MHz, and 13C NMR spectra were recorded at 75.47 or
100.61 MHz using a Bruker spectrometer. ESI-MS spectra were obtained using an Applied
Biosystems QSTAR XL quadrupole time-of-flight mass instrument with acetonitrile as solvent.
2.1.2

Synthetic “Maps”

Scheme 2.1. Synthesis of quinone compounds 7 & 8 intended for self-immolative spacer.

Scheme 2.2. Synthesis of quinone–N-methylaniline 9 for spirolactam studies.
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Scheme 2.3. General Synthesis of Simple Quinones 1a–h, Quinone Propionic Acids 4a–h, Quinone Succinimide Propionates 5a–d,
and Quinone-DOPE lipids 6a–d.

a

NBS oxidation applies only to 2b→1c, 2e→1e, 2f→1f; compound 2g underwent oxidative iodination to 1g. b2e–g do not undergo
lactonization. Also note the following transformations (not explicitly shown): Bromination of 2a→2e and 2b→2f by Br2/HOAc;
Bromine ion displacement of 4e→4f via n-PrNH2/MeOH; Acetylation of 3a→3f using Ac2O/dry pyridine; Iodination of 3f→3g by
I2/CF3CO2Ag in DCM; Deacetylation of 3g→3h via HCl/MeOH.
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2.1.3

Experimental Details & Characterization Data
The synthetic procedures for compounds 3d and 4d are described in a previous

publication from our group.1 The melting point of 3d is 172.5–175 °C (corrected), and 4d is
112.9–114.8 °C (corrected). Literature references for the following synthetic procedures are
either cited at the end of the bold headings or next to the number designation of the compound.
General procedure for quinones 1c, e, f, and quinone propionic acids 4a–c, g:2
(4a). In a typical procedure, a solution of NBS (0.853 g, 4.8 mmol) in 10 mL of acetonitrile was
added dropwise to a stirred solution of 3a (1.0 g, 4.5 mmol) in 50 mL of 10% aqueous
acetonitrile. The reaction mixture was stirred at room temperature for 90 min, diluted to 110 mL
with water, and extracted with ether (4 × 30 mL). The combined ether extracts were washed
with 50 mL of water and saturated brine (2 × 50 mL) and dried over MgSO4. Solvent removal
with the aid of a rotary evaporator provided a yellow oil, which solidified after refrigeration.
Recrystallization from chloroform/hexane afforded 0.755 g (70%) of 4a as a bright yellow solid.
Mp. 69–72 °C (corrected).

1

H NMR (400 MHz, CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.00 (d,

3H, CH3), 2.19 (s, 3H, CH3), 3.07 (s, 2H, CH2), 6.47 (s, 1H, quinone H).

13

C NMR (100.61

MHz, CDCl3) δ 14.5 and 15.5 (quinone CH3), 29.1 (geminal CH3), 38.2 (quaternary C), 47.3
(CH2), 134.8 (quinone CH), 140.4 and 143.7 (quinone C-CH3), 150.8 (quinone C-propionic side
chain), 178.2 (C=O), 188.2 and 189.6 (quinone C=O). HRMS (ESI) m/z [M−H]−, calcd =
235.0970 (calcd for C13H15O4), obsd = 235.0975, −2.3 ppm error.
(4b). From starting material, 3b. Recrystallized from hexane. Yield 87%. Mp. 103.0–104.5 °C.
1

H NMR (400 MHz, CDCl3) δ 1.44 (s, 6H, geminal CH3), 1.94, 1.96, and 2.15 (s, 3H, CH3), 3.03

(s, 2H, CH2).

13

C NMR (100.61 MHz, CDCl3) δ 12.2, 12.6, and 14.4 (quinone CH3), 28.9

(geminal CH3), 38.1 (quaternary C), 47.4 (CH2), 138.5, 139.2, and 143.1 (quinone C-CH3), and
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152.2 (quinone C-propionic side chain), 179.1 (C=O), 187.6 and 191.0 (quinone C=O). HRMS
(ESI) m/z [M−H]−, calcd = 249.1126 (calcd for C14H17O4), obsd = 249.1132, −2.6 ppm error.
(4c). From starting material, 3c. Recrystallized from hexane. Yield 56%. Mp. 101.3–103.2 °C.
1

H NMR (400 MHz, CDCl3) δ 1.33 (s, 6H, geminal CH3), 2.01 (d, 6H, CH3), 2.96 (s, 2H, CH2),

6.54 (s, 1H, CH).

13

C NMR (75.47 MHz, CDCl3) δ 11.8 and 12.6 (quinone CH3), 28.0 (geminal

CH3), 36.8 (quaternary C), 44.9 (CH2), 132.2 (quinone CH), 139.7 and 142.4 (quinone C-CH3),
152.9 (quinone C-propionic side chain), 177.6 (C=O), 187.4 and 187.9 (quinone C=O). HRMS
(ESI) m/z [M−H]−, calcd = 237.1128 (calcd for C13H17O4), obsd = 237.1126, 1.0 ppm error.
(1c). From starting material, 2b. No purification necessary. Yield 88%. Mp. 28.5–29.8 °C. 1H
NMR (400 MHz, CDCl3) δ 2.01, 2.03, and 2.04 (d, 3H, CH3), 6.56 (q, 1H, CH).

13

C NMR

(100.61 MHz, CDCl3) δ 12.0 and 12.3 (adjacent CH3), 15.8 (CH3), 133.0 (CH), 140.7, 140.9 and
145.3 (C-CH3), 187.4 and 187.8 (C=O). HRMS (ESI) m/z [M+H]+, calcd = 151.0760 (calcd for
C9H11O2), obsd = 151.0753, 4.9 ppm error.
(1e). From starting material, 2e. Recrystallized from ethanol/water (yield 62%) and then
chromatographed using dichloromethane/hexanes (1:1) to remove the doubly brominated
species. Mp. 55.2–56.3 °C (corrected). 1H NMR (400 MHz, CDCl3) δ 2.09 (d, 3H, CH3), 2.25
(s, 3H, CH3), 6.78 (q, 1H, CH).

13

C NMR (100.61 MHz, CDCl3) δ 16.0 and 17.1 (CH3), 132.5

(CH), 135.9 and 145.9 (C-CH3), and 146.0 (C-Br), 179.2 and 184.5 (C=O). HRMS (ESI) m/z
[M+H]+, calcd = 214.9708 (calcd for C8H8O2 Br), obsd = 214.9702, 3.0 ppm error.
(1f). From starting material, 2f. Recrystallized from ethanol. Yield 47%. Mp. 78.2–78.6 °C.
1

H NMR (400 MHz, CDCl3) δ 2.06 and 2.09 (q, 3H, CH3), 2.23 (s, 3H, CH3).

13

C NMR (100.61

MHz, CDCl3) δ 12.64, 13.17 and 17.09 (CH3), 135.51 (C-Br), 140.90, 140.94 and 145.67 (CCH3), 179.48 and 184.34 (C=O).

HRMS (ESI) m/z [M+H]+, calcd = 228.9865 (calcd for

C9H10O2Br), obsd = 228.9869, −1.6 ppm error.
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(4g). From starting material, 3h (grease-contaminated). Even though TLC (16:4:1 hexs/ethyl
acetate/acetic acid) only showed one spot, 4g was loaded onto a 10 g/25 mL Flash SI II column
(FlashMaster) and initially flushed with hexanes to remove any residual grease from the starting
material. 4g was then eluted off the column with 1:4 ethyl acetate/hexanes to yield 0.023 g
(60%) as a yellow viscous liquid. 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 6H, geminal CH3), 2.18
(s, 3H, CH3), 2.24 (s, 3H, CH3), 3.02 (s, 2H, CH2).

13

C NMR (100.61 MHz, CDCl3) δ 14.60 and

22.12 (quinone CH3), 28.56 (geminal CH3), 38.66 (quaternary C), 47.20 (CH2), 121.61 (quinone
C-I), 139.40 (quinone C-CH3), 150.46 (quinone C-propionic side chain), 152.68 (quinone CCH3), 177.73 (C=O), 183.22 and 183.65 (quinone C=O). HRMS (ESI) m/z [M-H]−, calcd =
360.9921 (calcd for C13H14O4I), obsd = 360.9942, −5.8 ppm error.
(1g).3 A solution of 2g (1.0 g, 7.34 mmol) and iodine (1.86 g, 7.34 mmol) in 13 mL of ethanol
was stirred and heated to 60 °C under a condenser to prevent any loss of solvent. To this
solution, 4 mL of 30% hydrogen peroxide diluted with 2 mL of ethanol was added slowly over a
2 h period (1 mL was added dropwise every 20 min). The mixture was stirred at 70 °C for an
additional hour and was then cooled to 0–5 °C using an ice-salt bath. The dark brown solid was
collected via vacuum filtration, washed successively with 40 mL of a 5% NaHSO3 solution
(which turned the solid orange), 25 mL of water, and 5 mL of cold (0–5 °C) 70% aqueous
methanol. The crude product was dried and then recrystallized from hexanes to yield 0.710 g
(38%) of 1g as bright, shiny orange crystalline flakes. Mp. 70.4–71.6 °C (corrected). 1H NMR
(400 MHz, CDCl3) δ 2.07 and 2.11 (q, 3H, CH3), 2.32 (s, 3H, CH3).

13

C NMR (100.61 MHz,

CDCl3 ) δ 12.61, 13.76, and 22.90 (CH3), 121.48 (C-I), 140.04, 140.80, and 152.12 (C-CH3),
180.34 and 183.02 (C=O). HRMS (ESI) m/z [M+H]+, calcd = 276.9726 (calcd for C9H10O2I),
obsd = 276.9720, 2.3 ppm error.
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(2e).4 A solution of bromine (1.1 g, 6.88 mmol) in 3.4 mL of acetic acid was added dropwise to
a stirred solution of 2a (1.0 g, 7.25 mmol) in 20.3 mL of acetic acid. The mixture was stirred for
24 h* at room temperature, and then the acetic acid was rapidly removed (20 min) with the aid of
a rotary evaporator. The crude material was recrystallized from 40% ethanol in water to produce
a brownish-white solid (0.9 g, 60%). *NOTE: The literature reference4 indicates a reaction
duration of 5 h, most likely to avoid generation of the doubly brominated species; however,
following the reaction progress by TLC revealed the presence of the doubly brominated species
even after only 2 h. Therefore, the purified product 2e is composed of about 6% (by 1H NMR)
of the doubly brominated species. Mp. 135–138 °C (corrected). 1H NMR (400 MHz, CDCl3) δ
2.20 and 2.34 (s, 3H, CH3), 4.35 and 5.17 (s, 1H, OH), 6.72 (s, 1H, aryl H).

13

C NMR (75.47

MHz, acetone-d6) δ 16.6 and 16.7 (CH3), 110.8 (C–Br), 115.8 (CH), 125.6 and 126.2 (C-CH3),
147.3 and 148.0 (C–OH). HRMS (ESI) m/z [M−H]−, calcd = 214.9707 (calcd for C8H8O2Br),
obsd = 214.9713, −3.0 ppm error.
(2f).4 A solution of bromine (1.0 g, 6.3 mmol) in 3.1 mL of acetic acid was added dropwise to a
stirred solution of 2b (1.0 g, 6.6 mmol) in 38 mL of acetic acid. The reaction mixture was stirred
at room temperature for 5 h, and then the acetic acid was rapidly removed (20 min) with the aid
of a rotary evaporator. The crude material was recrystallized from 45% ethanol in water to
produce a blackish-orange solid, which was then washed with chloroform to remove the black
impurities.

The purified product (2.61 g) was achieved in 60% yield.

Mp. 156–158 °C

(decomposes, blackens). 1H NMR (400 MHz, CDCl3) δ 2.16, 2.24, and 2.34 (s, 3H, CH3), 4.30
and 5.29 (s, 1H, OH).

13

C NMR (75.47 MHz, CDCl3) δ 12.28, 13.02 and 16.26 (CH3), 110.60

(C-Br), 120.41, 121.68 and 122.95 (C-CH3), 144.33 and 145.48 (C–OH). HRMS (ESI) m/z
[M−H]−, calcd = 228.9863 (calcd for C9H10O2Br), obsd = 228.9869, −2.8 ppm error.
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(2h).5 1h (3.0 g, 16.5 mmol) was dissolved in a mixture of 45 mL of ether and 23 mL of
methanol and was then added at room temperature to a stirring solution of sodium borohydride
(3.12 g, 82.4 mmol) in 89 mL of water. After 1 h of stirring, the mixture was poured into a
separatory funnel, and the layers were allowed to separate. To help better distinguish between
layers, 30 mL of ether was added and then the ether layer was removed. The aqueous phase was
extracted again with 30 mL of ether. The aqueous layer was then acidified with the slow
addition of 37% HCl and extracted with ether (2 × 30 mL). The combined organic extracts were
washed with saturated brine (2 × 75 mL) and dried over MgSO4. Solvent removal with a rotary
evaporator gave 2.46 g (81%) of the hydroquinone as a whitish-orange solid. The crude material
was used directly in the preparation of 3e. Mp. 75.4–76.5 °C.

1

H NMR (400 MHz, CDCl3) δ

2.18 (s, 3H, CH3), 3.89 and 3.92 (s, 3H, OCH3), 5.13 and 5.29 (s, 1H, OH), 6.49 (s, 1H, aryl H).
13

C NMR (100.61 MHz, CDCl3) δ 15.4 (CH3), 60.8 and 60.9 (OCH3), 111.4 (benzene CH), 119.4

(benzene C-CH3), 137.2 (C–OCH3), 139.1 (C–OH), 140.4 (C–OCH3), 141.6 (C–OH). HRMS
(ESI) m/z [M+H]+, calcd = 185.0815 (calcd for C9H13O4), obsd = 185.0808, 4.0 ppm error.
(3a).5 Methanesulfonic acid (20 mL) was heated to 70 °C in an oil bath with stirring. Once this
temperature was reached, 2a (2.0 g, 14.5 mmol) and 3,3-dimethylacrylic acid (1.55 g, 15.5
mmol) were added and the reaction continued to stir at 70 °C for 2 h. The mixture diluted to 200
mL with water and extracted with ethyl acetate (3 × 50 mL). The extracts were washed with 100
mL of water, saturated NaHCO3 solution (2 × 100 mL), and 100 mL of saturated brine and dried
over MgSO4. Solvent removal with the aid of a rotary evaporator gave a tan solid, which was
recrystallized from 40% CHCl3 in hexane to give 2.14 g (67%). Mp. 144.5–145.7 °C. 1H NMR
(400 MHz, CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.23 and 2.38 (s, 3H, CH3), 2.57 (s, 2H, CH2),
4.50 (s, 1H, OH), 6.73 (s, 1H, aryl H).

13

C NMR (100.61 MHz, CDCl3) δ 14.4 and 15.9

(benzene CH3), 27.7 (geminal CH3), 35.4 (quaternary C), 46.0 (CH2), 116.8 (benzene C-CH3),
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122.0 (benzene CH), 122.5 (benzene C-CH3), 128.6 (benzene C-lactone), 144.8 (C–O), 149.2
(C–OH), 168.7 (C=O). HRMS (ESI) m/z [M−H]−, calcd = 219.1020 (calcd for C13H15O3), obsd
= 219.1026, −2.9 ppm error.
(3b).5 Methanesulfonic acid (100 mL) was heated to 70 °C in an oil bath with stirring. Once this
temperature was reached, 2b (10.0 g, 65.7 mmol) and 3,3-dimethylacrylic acid (7.5 g, 74.9
mmol) were added and the reaction continued to stir at 70 °C for 2 h. The mixture was diluted to
1250 mL with water and extracted with ethyl acetate (3 × 250 mL). The extracts were washed
with 400 mL of water, saturated NaHCO3 solution (2 × 100 mL), and saturated brine (2 × 150
mL) and dried over MgSO4. Solvent removal with the aid of a rotary evaporator gave a tan solid,
which was purified by washing with 30% CHCl3 in hexane to give 12.0 g (83%). Mp. 180–182
°C. 1H NMR (400 MHz, CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.18, 2.22, and 2.36 (s, 3H, CH3),
2.55 (s, 2H, CH2), 4.51 (s, 1H, OH).

13

C NMR (75.47 MHz, CDCl3) δ 12.5, 12.7, and 14.7

(benzene CH3), 27.8 (geminal CH3), 35.6 (quaternary C), 46.2 (CH2), 119.3, 122.2, and 123.5
(benzene C-CH3), 128.3 (benzene C-lactone), 143.6 (C–O), 149.1 (C–OH), and 169.3 (C=O).
HRMS (ESI) m/z [M−H]−, calcd = 233.1177 (calcd for C14H17O3), obsd = 233.1183, −2.7 ppm
error.
(3e).5 Methanesulfonic acid (18 mL) was heated to 70 °C in an oil bath with stirring. Once this
temperature was reached, 2h (1.5 g, 8.14 mmol) and methyl 3,3-dimethylacrylate (0.976 g, 8.55
mmol) were added and the reaction continued to stir at 70 °C for 2 h. The mixture was diluted to
135 mL with water and extracted with ether (2 × 100 mL). The extracts were washed with 80
mL of water, saturated NaHCO3 solution (4 × 25 mL), and 65 mL of saturated brine and dried
over MgSO4. Solvent removal with the aid of a rotary evaporator gave a tan solid, which was
recrystallized from methanol to give 1.22 g (56%). Mp. 158–161 °C.

1

H NMR (400 MHz,

CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.34 (s, 3H, CH3), 2.58 (s, 2H, CH2), 3.91 and 3.97 (s, 3H,
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OCH3), 5.74 (s, 1H, OH).

13

C NMR (100.61 MHz, CDCl3) δ 13.7 (benzene CH3), 27.7 (geminal

CH3), 35.8 (quaternary C), 45.9 (CH2), 61.2 and 61.5 (OCH3), 116.4 (benzene C-CH3), 126.4
(C–O), 138.3 (benzene C-lactone), 138.4 (benzene C-OCH3) 138.6 (C–OH), 143.9 (benzene COCH3), 167.7 (C=O). HRMS (ESI) m/z [M+H]+, calcd = 267.1233 (calcd for C14H19O5), obsd =
267.1227, 2.4 ppm error.
(4h).5 Pyridinium dichromate (3.17 g, 8.45 mmol) was dissolved with stirring in 7 mL of DMF.
To this solution, lactone 3e (0.5 g, 1.88 mmol) in 2 mL DMF was added at room temperature.
After 4.5 h of stirring, the reaction mixture was diluted to 400 mL with water and extracted with
ether (3 × 50 mL). The combined organic extracts were washed with 40 mL of water and then
saturated sodium bicarbonate (5 × 25 mL). The combined bicarbonate washings were made
slightly acidic by the addition of 37% HCl, and the resulting aqueous solution was extracted with
ether (4 × 25 mL). These organic extracts were washed with 30 mL of brine and dried over
MgSO4. Solvent removal with the aid of a rotary evaporator gave a yellow viscous residue
(0.1733 g, 33%). The crude material was then purified on a 10 g/25 mL Flash Si II column
(60:1) using the FlashMaster chromatography system using hexanes / ethyl acetate / acetic acid
(16:4:1) to give 22 mg (4%) as a yellow viscous residue. 1H NMR (400 MHz, CDCl3) δ 1.45 (s,
6H, geminal CH3), 2.15 (s, 3H, CH3), 3.06 (s, 2H, CH2), 3.90 (s, 3H, OCH3), 3.96 (s, 3H, OCH3).
13

C NMR (100.61 MHz, CDCl3) δ 14.0 (quinone CH3), 28.9 (geminal CH3), 38.2 (quaternary C),

47.2 (CH2), 60.4 and 60.9 (OCH3), 137.7 (quinone C-CH3), 142.4 and 145.3 (quinone C-OCH3),
149.8 (C-propionic side chain), 177.9 (C=O), 184.5 and 186.3 (quinone C=O). HRMS (ESI) m/z
[M+H]+, calcd = 283.1182 (calcd for C14H19O6), obsd = 283.1176, 2.3 ppm error.
(3c). 2c (3.2 g, 23 mmol) and 3,3-dimethylacrylic acid (4.6 g, 46 mmol) were dissolved in 250
mL of toluene along with 1.3 mL of concentrated sulfuric acid, and the mixture was refluxed for
2 h. The reaction mixture was washed with water (2 × 100 mL), 5% NaHCO3 solution (4 × 100
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mL), and brine solution (2 × 100 mL), and then the toluene layer was dried over MgSO4.
Solvent removal with a rotary evaporator afforded a dark black solid, which was recrystallized
from 30% CHCl3 in hexane to give 2.33 g (48%) of a tan crystalline solid. Mp. 146.0–149.5 °C.
1

H NMR (400 MHz, CDCl3) δ 1.31 (s, 6H, geminal CH3), 2.17 and 2.25 (s, 3H, CH3), 2.57 (s,

2H, CH2), 4.60 (s, 1H, OH), 6.61 (s, 1H, aryl H).

13

C NMR (100.61 MHz, CDCl3) δ 11.8 and

12.3 (CH3), 27.6 (geminal CH3), 33.1 (quaternary C), 43.7 (CH2), 107.8 (benzene CH), 122.6
and 126.4 (C-CH3), 129.6 (C–O), 142.8 (benzene C-lactone), 150.2 (C–OH), 169.0 (C=O).
HRMS (ESI) m/z [M−H]−, calcd = 219.1020 (calcd for C13H15O3), obsd = 219.1026, −2.9 ppm
error.
(4e).5 3a (1.0 g, 4.5 mmol) was dissolved in 37 mL of acetic acid, and with stirring at room
temperature a solution of bromine (1.6 g, 10 mmol) in 6 mL of acetic acid was slowly added
dropwise. After the reaction had stirred for 23 h, the mixture was diluted to 215 mL with water
and extracted with dichloromethane (3 × 25 mL). The combined organic extracts were washed
with 50 mL of water and then saturated NaHCO3 solution (5 × 40 mL).

The combined

bicarbonate washes were made just slightly acidic by the slow addition of 37% HCl, and the
resulting aqueous solution was extracted with dichloromethane (4 × 25 mL). The combined
organic extracts were washed with 50 mL of water and then dried with MgSO4. Solvent removal
with a rotary evaporator afforded a yellow viscous residue (1.13 g, 71%), which solidified
(crystalline) after refrigeration. The entire crude material was not purified as per the literature
reference;5 however, a small-scale recrystallization was successfully achieved from
dichloromethane/hexanes in order to obtain X-ray crystallographic data.

1

H NMR (400 MHz,

CDCl3) δ 1.47 (s, 6H, geminal CH3), 2.18 and 2.20 (s, 3H, CH3), 3.06 (s, 2H, CH2).

13

C NMR

(100.61 MHz, CDCl3) δ 14.6 and 16.6 (quinone CH3), 28.8 (geminal CH3), 38.7 (quaternary C),
47.2 (CH2), 136.2 (C–Br), 139.7 and 144.0 (C-CH3), 152.5 (quinone C-propionic side chain),
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178.2 (quinone C=O), 182.4 (C=O), 184.6 (quinone C=O). HRMS (ESI) m/z [M−H]−, calcd =
313.0075 (calcd for C13H14O4Br), obsd = 313.0080, −1.7 ppm error.
(4f).5 4e (0.2 g, 0.635 mmol) was dissolved in 5.3 mL of methanol, and then propylamine (0.188
g, 3.2 mmol) was added with stirring at room temperature. The flask was tightly stoppered, and
stirring was continued for 46 h. The mixture was diluted to 74 mL with water, 5.3 mL of 5%
HCl was added, and the resulting solution was extracted with ethyl acetate (3 × 15 mL). The
combined organic extracts were washed with 35 mL of saturated brine and then dried with
MgSO4. Solvent removal with a rotary evaporator afforded a deep red viscous residue, which
was chromatographed on a silica gel column (50:1) using hexanes / ethyl acetate / acetic acid
(16:4:1). Concentration of the major red fraction afforded a viscous residue, which was taken up
in 20 mL of dichloromethane and washed with water (2 × 40 mL) to remove acetic acid. After
drying with MgSO4, the solvent was removed with a rotary evaporator, which gave a red viscous
residue (0.082 g, 43%).

1

H NMR (400 MHz, CDCl3) δ 0.96 (s, 3H, propyl CH3), 1.45 (s, 6H,

gem CH3), 1.59 (m, 2H, CH2CH2CH3), 2.02 (s, 3H, quinone CH3), 2.20 (s, 3H, quinone CH3),
2.99 (s, 2H, CH2), 3.37 (t, 2H, NCH2).

13

C NMR (100.61 MHz, CDCl3) δ 10.4 (quinone CH3),

11.1 (propyl CH3), 15.2 (quinone CH3), 24.1 (CH2CH2CH3), 29.2 (geminal CH3), 38.1
(quaternary C), 46.9 (N-CH2), 47.0 (CH2), 107.6 (quinone C-CH3), 143.1 (quinone Cpropylamine), 146.2 (quinone C-CH3), 146.4 (quinone C-propionic side chain), 177.3 (C=O),
185.9 and 187.1 (quinone C=O).

HRMS (ESI) m/z [M+H]+, calcd = 294.1706 (calcd for

C16H24NO4), obsd = 294.1699, 2.5 ppm error.
(3f).6-7 To a stirred solution of 3a (0.2 g, 0.91 mmol) in 3.2 mL of dry pyridine, acetic anhydride
(3.3 mL) was added at room temperature. A drying tube was used to stopper the reaction, and
the mixture was allowed to stir for 24 h. Then the mixture was poured into 75 mL of cold water
and extracted with ethyl acetate (3 × 50 mL). The combined organic extracts were washed with
69

saturated brine (2 × 50 mL) and dried over MgSO4. Solvent removal with a rotary evaporator
afforded a brownish liquid (still contains pyridine), which was put under high-vacuum and then
chromatographed on a silica gel column (50:1) using ethyl acetate / hexanes (1:4).
Concentration of the middle fraction (Rf ≈ 0.30) afforded a colorless sticky residue (0.21 g,
97%), which solidified into a whitish solid after refrigeration. Mp. 86–90 °C (corrected).

1

H

NMR (400 MHz, CDCl3) δ 1.45 (s, 6H, geminal CH3), 2.12 and 2.25 (s, 3H, CH3), 2.36 (s, 3H,
acetyl CH3), 2.59 (s, 2H, CH2), 6.81 (s, 1H, aryl H).

13

C NMR (100.61 MHz, CDCl3) δ 15.0 and

16.3 (benzene CH3), 20.4 (acetate CH3), 27.7 (geminal CH3), 35.5 (quaternary C), 45.7 (CH2),
117.4 (benzene CH), 128.5 and 128.7 (benzene C-CH3), and 130.1 (benzene C-lactone), 145.1
and 148.8 (benzene C–O), 168.0 (lactone C=O), 168.9 (acetate C=O).

HRMS (ESI) m/z

[M+H]+, calcd = 263.1284 (calcd for C15H19O4), obsd = 263.1277, 2.8 ppm error.
(3g).8 To an ice-cooled mixture of 3f (1.13 g, 4.30 mmol) and silver trifluoroacetate (1.09 g,
4.94 mmol) in 28 mL of dichloromethane, a solution of I2 (1.00 g, 3.95 mmol) in 28 mL of
dichloromethane was added under stirring. After stirring for 3.5 h at room temperature, silver
iodide (yellow precipitate) was vacuum-filtered off and washed with dichloromethane. (Several
filtrations might be necessary in order to completely remove silver iodide.) The combined
filtrate and washings were poured into a separatory funnel, washed with aqueous NaHCO3 (3 ×
150 mL) and water (2 × 150 mL), and then dried over MgSO4. The solvent was removed with a
rotary evaporator, and the crude material was purified on a silica gel column (25:1) using
dichloromethane as the eluent. Concentration of the first fraction (Rf ≈ 0.51) afforded a colorless
sticky residue (1.0 g, 65%), which solidified into a whitish solid after refrigeration. Mp. 160–
165 °C (corrected).

1

H NMR (400 MHz, CDCl3) δ 1.45 (d, 6H, geminal CH3), 2.22 (s, 3H,

benzene CH3), 2.31 (s, 3H, acetyl CH3), 2.36 (s, 3H, benzene CH3), 2.58 (d, 2H, CH2).

13

C NMR

(100.61 MHz, CDCl3) δ 15.2 and 20.5 (benzene CH3), 22.7 (acetyl CH3), 27.4 (geminal CH3),
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36.3 (quaternary C), 45.7 (CH2), 90.7 (C–I), 129.0 and 129.3 (benzene C-CH3), 134.3 (benzene
C-lactone), 144.3 and 148.3 (benzene C–O), 166.8 (acetyl C=O), 168.7 (lactone C=O). HRMS
(ESI) m/z [M+H]+, calcd = 389.0251 (calcd for C15H18O4I), obsd = 389.0244, 1.9 ppm error.
(3h).9 3g (0.1 g, 0.258 mmol) was dissolved in a minimal amount of dichloromethane because
its solubility in methanol is limited. To this solution, 7.4 mL of methanol and then 0.3 mL of
HCl were added with stirring. The solution was allowed to stir at room temperature for 5 days;
although, monitoring by TLC (eluent = DCM) for reaction completion is recommended. The
reaction was quenched with 10 mL of cold water and extracted with ethyl acetate (2 × 20 mL).
The combined organic extracts were washed with 50 mL of brine and then dried over Na2SO4.
The solvent was removed with a rotary evaporator, and the crude material was purified on a 25
g/150 mL Flash Si II column (~300:1) using the FlashMaster chromatography system using
chloroform/ethyl acetate (30:1) to give 36.2 mg (40%) as a white solid. *The purified product
was contaminated with grease but used anyway for the synthesis of 4g.

1

H NMR (400 MHz,

CDCl3) δ 1.47 (s, 6H, geminal CH3), 2.36 (s, 3H, benzene CH3), 2.47 (s, 3H, benzene CH3), 2.57
(s, 2H, CH2), 4.61 (s, 1H, OH).

13

C NMR (100.61 MHz, CDCl3) δ 14.7 and 22.0 (benzene CH3),

27.5 (geminal CH3), 36.2 (quaternary C), 46.1 (CH2), 90.5 (benzene C-I), 122.2 and 126.8
(benzene C-CH3) 129.5 (benzene C-lactone), 144.6 (benzene C-O), 148.6 (benzene C-OH),
167.4 (lactone C=O). HRMS (ESI) m/z [M+H]+, calcd = 347. 0145 (calcd for C13H16O3I ), obsd
= 347.0138, 2.1 ppm error.
General procedure for quinone succinimide propionates 5a–d:5
(5c). In a typical procedure, dicyclohexylcarbodiimide (0.440 g, 2.13 mmol) was added to a
solution of quinone propionic acid 4e (0.594 g, 1.9 mmol) and N-hydroxysuccinimide (0.239 g,
2.08 mmol) in 30 mL of dry THF at 0 °C under argon. The mixture was stirred for 20 h and
allowed to gradually warm to room temperature. To remove dicyclohexylurea, the solution was
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vacuum filtered, evaporated (with the aid of a rotary evaporator), treated with 10 mL of ethyl
acetate, and vacuum filtered again. This cycle was repeated three times, or until all of the
dicyclohexylurea was removed. Final evaporation of the solvent and recrystallization of the
residue from ethyl acetate/hexanes afforded 0.527 g (68%) of 5c as a bright yellow solid.
1

H NMR (400 MHz, CDCl3) δ 1.56 (s, 6H, geminal CH3), 2.17 (s, 3H, CH3), 2.22 (s, 3H, CH3),

2.78 (s, 4H, CH2), 3.25 (s, 2H, CH2).

13

C NMR (100.61 MHz, CDCl3) δ 14.5, 16.9, 25.5, 29.5,

40.1, 44.1, 136.4, 141.6, 144.5, 149.7, 167.4, 168.8, 181.8, 184.6. HRMS (ESI) m/z [M+H]+,
calcd = 412.0396 (calcd for C17H19BrNO6), obsd = 412.0401, –1.1 ppm error.
(5a). From starting material, 4a. Purified on a 70 g/150 mL Flash Si II column (~45:1) using the
FlashMaster chromatography system with dichloromethane/ethyl acetate (9:1). (As an alternative
to column chromatography, crude 5a can be recrystallized from ethyl acetate/hexanes). Yield
61%. 1H NMR (400 MHz, CDCl3) δ 1.55 (s, 6H, geminal CH3), 1.99 (s, 3H, CH3), 2.21 (s, 3H,
CH3), 2.79 (s, 4H, CH2), 3.29 (s, 2H, CH2), 6.50 (s, 1H, CH).

13

C NMR (100.61 MHz, CDCl3) δ

14.4, 15.6, 25.6, 29.6, 39.4, 44.2, 135.0, 141.7, 143.9, 148.7, 167.6, 168.9, 188.2, 189.2. HRMS
(ESI) m/z [M+Na]+ calcd = 356.1104 (calcd for C17H19NNaO6), obsd = 356.1105, –0.3 ppm
error.
(5b). From starting material, 4b. Recrystallized from ethyl acetate/hexanes. Yield 82%.

1

H

NMR (400 MHz, CDCl3) δ 1.53 (s, 6H, geminal CH3), 1.96 (s, 3H, CH3), 2.18 (s, 3H, CH3), 2.78
(s, 4H, CH2), 3.29 (s, 2H, CH2).

13

C NMR (100.61 MHz, CDCl3) δ 12.3, 12.7, 14.4, 25.7, 29.3,

44.3, 138.9, 140.5, 143.0, 150.1, 167.8, 169.0, 187.5, 190.4. HRMS (ESI) m/z [M+Na]+, calcd =
370.1261 (calcd for C18H21NNaO6), obsd = 370.1262, –0.3 ppm error.
(5d). From starting material, 4f. Purified on a 70 g/150 mL Flash Si II column (~270:1) using
the FlashMaster chromatography system with dichloromethane/ethyl acetate (14:1). Yield 63%.
1

H NMR (400 MHz, CDCl3) δ 0.96 (t, 3H, CH3), 1.52 (s, 6H, geminal CH3), 1.61 (m, 2H, CH2),
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2.03 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.79 (s, 4H, CH2), 3.25 (s, 2H, CH2), 3.38 (q, 2H, CH2),
5.24 (t, 1H, NH).

13

C NMR (100.61 MHz, CDCl3) δ 10.6, 11.2, 15.2, 24.0, 25.6, 29.2, 38.5,

44.0, 47.0, 107.3, 144.3, 144.8, 145.9, 167.6, 169.0, 185.6, 187.0. HRMS (ESI) m/z [M+H]+,
calcd = 391.1870 (calcd for C20H27N2O6), obsd = 391.1847, 6.0 ppm error.
General procedure for quinone–dioleoylphosphatidylethanolamine lipids 6a–d:1
(6a). In a typical procedure, triethylamine (78.1 mg, 0.77 mmol) and then 5a (54.6 mg, 0.164
mmol) were added to a cooled solution (0 °C) of dioleoylphosphatidylethanolamine (115 mg,
0.154 mmol) in 5 mL of dry DCM under argon. The reaction was stirred for 4–6 h and allowed
to gradually warm to room temperature. The reaction mixture was diluted with DCM to 50 mL,
then extracted with 5% NaHCO3 (1 × 50 mL). The organic layer was dried with Na2SO4, and the
solvent was removed with the aid of a rotary evaporator. The crude residue was loaded onto a 10
g/25 mL Flash Si II column (~50:1) using the FlashMaster chromatography system and eluted
via a gradient of 1:1 DCM/ethyl acetate (to elute any unreacted 5a, if any) followed by 3:1:2
DCM/MeOH/hexanes (to elute the pure product). The combined fractions were evaporated to
dryness and dried under high vacuum (for at least 1 h) to afford 0.122 g (82%) of 6a as a bright
yellow wax. 1H NMR (400 MHz, CDCl3) δ 0.88 (t, 6H, CH3), 1.27 (m, 40H, CH2), 1.41 (s, 6H,
geminal CH3), 1.57 (m, 4H, CH2), 1.99 (q, 8H, CH2), 2.01 (d, 3H, CH3), 2.15 (s, 3H, CH3), 2.29
(t, 4H, CH2), 2.89 (s, 2H, CH2), 3.37 (d, 2H, CH2), 3.84 (d, 2H, CH2), 3.95 (d, 2H, CH2), 4.13 (t,
1H, H–CH), 4.40 (t, 1H, H–CH), 5.26 (m, 1H, CH), 5.34 (m, 4H, CH), 6.56 (s, 1H, CH).

13

C

NMR (100.61 MHz, CDCl3) δ 14.1, 14.4, 15.6, 22.7, 24.8, 24.9, 27.2, 29.0, 29.2, 29.3, 29.5,
29.8, 31.9, 34.1, 34.2, 38.4, 39.8, 48.8, 62.9, 63.7, 64.8, 70.4, 129.6, 130.0, 135.2, 138.9, 143.6,
152.9, 172.8, 173.5, 173.8, 188.0, 190.5. HRMS (ESI) m/z [M−Na]−, calcd = 960.6335 (calcd
for C54H91NO11P–), obsd = 960.6352, –1.8 ppm error.
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(6b). From starting material, 5b. Purified using identical procedure as 6a. Yield 96%.

1

H

NMR (400 MHz, CDCl3) δ 0.88 (t, 6H, CH3), 1.27 (m, 40H, CH2), 1.37 (s, 6H, geminal CH3),
1.57 (m, 4H, CH2), 1.94 (s, 6H, CH3), 2.00 (q, 8H, CH2), 2.10 (s, 3H, CH3), 2.29 (t, 4H, CH2),
2.84 (s, 2H, CH2), 3.38 (d, 2H, CH2), 3.85 (d, 2H, CH2), 3.93 (t, 2H, CH2), 4.16 (t, 1H, H–CH),
4.42 (t, 1H, H–CH), 5.28 (m, 1H, CH), 5.34 (m, 4H, CH).

13

C NMR (100.61 MHz, CDCl3) δ

12.3, 12.9, 14.3, 22.9, 25.1, 27.4, 28.8, 29.5, 29.7, 30.0, 32.1, 34.3, 34.5, 38.1, 39.8, 48.7, 63.1,
63.8, 65.2, 70.7, 129.8, 130.2, 137.5, 138.0, 143.7, 154.0, 172.9, 173.9, 174.2, 187.6, 191.5.
HRMS (ESI) m/z [M−Na]−, calcd = 974.6492 (calcd for C55H93NO11P–), obsd = 974.6485, 0.7
ppm error.
(6c). From starting material, 5c. Purified using identical procedure as 6a, except that a reddishbrown (slightly more nonpolar) impurity was removed from the head of the product plug with
the second eluent. Yield 38%. 1H NMR (400 MHz, CDCl3) δ 0.87 (t, 6H, CH3), 1.27 (m, 40H,
CH2), 1.40 (s, 6H, CH3), 1.58 (m, 4H, CH2), 1.99 (q, 8H, CH2), 2.14 (s, 6H, CH3), 2.29 (t, 4H,
CH2), 2.87 (s, 2H, CH2), 3.39 (d, 2H, CH2), 3.88 (d, 2H, CH2), 3.96 (t, 2H, CH2), 4.17 (t, 1H, H–
CH), 4.41 (t, 1H, H–CH), 5.33 (m, 1H, CH), 5.33 (m, 4H, CH), 7.36 (bs, 1H, NH).

13

C NMR

(100.61 MHz, CDCl3) δ 14.1, 14.4, 16.6, 22.7, 24.9, 27.2, 28.5, 29.2, 29.3, 29.6, 29.8, 31.9, 34.1,
34.3, 36.0, 38.7, 39.8, 48.5, 63.0, 63.7, 64.7, 70.5, 129.0, 130.0, 136.6, 137.5, 143.4, 154.7,
172.6, 173.6, 173.8, 182.6, 184.6. HRMS (ESI) m/z [M−Na]−, calcd = 1038.5440 (calcd for
C54H90BrNO11P–), obsd = 1038.5453, –1.3 ppm error.
(6d). From starting material, 5d. Purified using identical procedure as 6a. Yield 77%.

1

H

NMR (400 MHz, CDCl3) δ 0.88 (t, 6H, CH3), 0.93 (t, 3H, CH3), 1.28 (m, 40H, CH2), 1.39 (s, 6H,
geminal CH3), 1.58 (m, 2H, CH2), 1.58 (m, 4H, CH2), 1.71 (s, 6H, CH3), 2.00 (q, 8H, CH2), 2.29
(t, 4H, CH2), 2.79 (s, 2H, CH2), 3.34 (q, 2H, CH2), 3.34 (d, 2H, CH2), 3.82 (d, 2H, CH2), 3.93 (t,
2H, CH2), 4.14 (t, 1H, H–CH), 4.40 (t, 1H, H–CH), 5.27 (m, 1H, CH), 5.34 (m, 4H, CH).
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13

C

NMR (100.61 MHz, CDCl3) δ 8.5, 10.4, 11.2, 14.1, 15.0, 22.7, 24.2, 24.9, 25.0, 27.2, 29.2, 29.3,
29.5, 29.8, 31.9, 34.1, 34.2, 37.9, 39.8, 45.6, 46.8, 48.5, 53.4, 62.8, 63.7, 64.8, 70.4, 106.8, 129.6,
130.0, 140.6, 147.3, 148.4, 172.4, 173.3, 173.6, 185.8. HRMS (ESI) m/z [M−Na]−, calcd =
1017.6914 (calcd for C57H98N2O11P–), obsd = 1017.6910, 0.4 ppm error.
(7).10 4-aminobenzyl alcohol (1.6 g, 12.90 mmol) and 5b (1.0 g, 2.88 mmol) were combined in a
3-neck round bottom flask and subjected to high vacuum for 40 mins. The flask was then purged
with argon gas, and 6 mL of dry THF was added via syringe. The reaction was stirred at room
temperature under argon and in the dark. After 3 days, the reaction mixture was diluted with
EtOAc (400 mL) and washed with water (6 × 200 mL) until most of the excess 4-aminobenzyl
alcohol was removed, as monitored by TLC of the organic layers (eluent = 2:1 DCM/EtOAc).
The organic layers were combined, dried with MgSO4, and then evaporated with the aid of a
rotarty evaporator. Recrystallization of the crude material from DCM/EtOAc afforded 0.689 g
(66 %) of 7 as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 1.50 (s, 6H, geminal CH3), 1.95 (s,
3H, CH3), 1.96 (s, 3H, CH3), 2.16 (s, 3H, CH3), 3.03 (s, 2H, CH2), 4.64 (s, 2H, CH2), 7.08 (s, 1H,
NH), 7.29 (d, 2H, CH), 7.40 (d, 2H, CH).

13

C NMR (100.61 MHz, CDCl3) δ 12.2, 12.7, 14.2,

29.2, 38.4, 50.4, 64.9, 119.9, 127.8, 136.8, 137.1, 138.3, 138.4, 143.2, 152.9, 170.2, 187.5, 191.6.
HRMS (ESI) m/z [M+H]+, calcd = 356.1863 (calcd for C21H26NO4), obsd = 356.1864, –0.2 ppm
error.
(8).11-12 Compound 7 (0.1 g, 0.28 mmol) was put into a 50 mL 3-neck round bottom flask and
subjected to high vacuum for 30 mins. The flask was then purged with argon gas, and 5 mL of
dry THF was added with stirring. 4-nitrophenyl chloroformate (0.074 g, 0.37 mmol) and then
dry pyridine (0.029 g, 0.37 mmol) were added to the flask, and the reaction continued to stir at
room temperature for 18 h in the dark. The reaction mixture was vacuum filtered to remove the
precipitate and then concentrated using a rotary evaporator to yield a yellow residue. The crude
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material had to be chromatographed on three different columns. Column (1): 50 g/150 mL Flash
Si II using 60:1 DCM/MeOH. Column (2): 25 g/150 mL Flash Si II using 60:1 DCM/MeOH.
Column (3): 10 g/25 mL Flash Si II using 100:1 DCM/MeOH. After each column, fractions
containing a reasonable amount of the product (Rf = 0.3, yellowish brown) were combined and
purified using the next column to eventually remove all of the impurities. The final fractions
were then combined and concentrated using a rotary evaporator to yield ~94 mg (64%) of 8. 1H
NMR (400 MHz, CDCl3) δ 1.50 (s, 6H, geminal CH3), 1.92 (s, 3H, CH3), 1.94 (s, 3H, CH3), 2.16
(s, 3H, CH3), 3.07, (s, 2H, CH2), 5.22 (s, 2H, CH2), 7.36 (d, 4H, CH), 7.44 (d, 2H, CH), 8.26 (d,
2H, CH).

13

C NMR (100.61 MHz, CDCl3) δ 12.2, 12.7, 14.2, 29.1, 38.4, 50.4, 70.6, 119.9,

121.8, 125.3, 129.7, 129.9, 138.3, 138.4, 143.2, 145.4, 152.4, 152.8, 155.5, 170.5, 187.5, 191.5.
HRMS (ESI) m/z [M+H]+, calcd = 521.1925 (calcd for C28H29N2O8), obsd = 521.1907, 3.5 ppm
error.
(9).13 4b (0.4 g, 1.60 mmol) was dissolved in 110 mL dry DCM, to which was added Nmethylmorpholine (0.5 g, 4.79 mmol). The mixture was cooled to –55 °C in a dry ice–2propanol bath. Isobutyl chloroformate (0.26 g, 1.92 mmol) was then added, followed by addition
of N-methylaniline (0.5 g, 4.79 mmol) after 10 mins. The reaction mixture was stirred for 1 hr in
the dark. After which, the reaction was allowed to warm to room temperature with the aid of a
water bath and then evaporated on a rotary evaporator. The resulting dark orange solid residue
was taken up in 70 mL of chloroform and washed with water (100 mL), 5% HCl (100 mL), 5%
NaHCO3 (100 mL), and brine (100 mL). The organic layer was dried over MgSO4, and the
solvent was evaporated to yield a yellow residue. The crude material was loaded onto a 70 g/150
mL Flash Si II column and purified using the FlashMaster chromatography system with
ether/hexanes (2:5). The main yellow plug that eluted with an Rf = 0.25 was collected, and the
solvent was evaporated to yield 0.268 g (49%) of 9. 1H NMR (400 MHz, CDCl3) δ 1.29 (s, 6H,
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geminal CH3), 1.96 (s, 3H, CH3), 2.00 (s, 3H, CH3), 2.09 (s, 3H, CH3), 2.73 (s, 2H, CH2), 3.15 (s,
3H, NCH3), 7.19 (d, 2H, CH), 7.35 (t, 1H, CH), 7.44 (t, 2H, CH).

13

C NMR (100.61 MHz,

CDCl3) δ 12.1, 12.7, 14.1, 28.4, 37.1, 38.0, 47.6, 127.5, 127.8, 129.8, 136.2, 137.7, 143.6, 144.0,
154.8, 172.1, 187.7, 191.2. HRMS (ESI) m/z [M+H]+, calcd = 340.1913 (calcd for C21H26NO3),
obsd = 340.1889, 7.2 ppm error.
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HR-ESI--ToF-MS da
ata for 9
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M+H
M
H+

HR-ESI--ToF-MS da
ata for 7
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M+Na+

HR-ESI--ToF-MS da
ata for 5a
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M–

HR-ESII-ToF-MS data
d
for 6a
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M+H+

HR-ESI--ToF-MS da
ata for 5c
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M+H+

HR-ESI--ToF-MS da
ata for 5d
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M–

HR-ESI--ToF-MS da
ata for 6c

181

M–

HR-ESI--ToF-MS da
ata for 6d
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2.2.3

1

H NMR Stu
udies of Spirrolactam Foormation

A colleague in our reseaarch group was
w conductting enzymee (NQO1) kinetic
k
studiees on
quinone compound 7 and noticedd that, over time, the color of the buuffered aqueeous solutionn of 7
changed from its chaaracteristic yellow
y
to coolorless; morreover, the results
r
of thee enzyme kiinetic
assays were
w
unusuall. These obbservations suggested
s
a loss of quinnone charactter, possiblyy as a
result of conversion of
o 7 to anothher species or
o formation of a degradaation producct. To investtigate
the status of 7 in aq
queous mediia, 1H NMR
R spectra weere obtainedd using mixttures of D2O and
DMSO-dd6 (to improve solubilityy). In fact, it was founnd that 7 unnderwent rappid cyclizatioon to
form its spirolactam
s
in aqueous solution,
s
as seen
s
by the 1H NMR speectrum in Figgure 2.1.

1
Figure 2.1.
2
H NMR
R (400 MHz) spectrum of
o 7 in 70% DMSO-d
D
quired roughhly 15
6/30% D2O acq
min afterr preparing the samplee. Integratioon indicatess approximaately 50% conversion too the
spirolactaam denoted in the inset. Signals (h) and (j) overrlap with siggnals from coompound 7.
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It was alsso observed that the ratee of spirolacttam formatioon increasedd as the solution became more
aqueous in nature (i.ee. higher perrcentages of D2O), as evvidenced in Figure
F
2.2.

2
Comp
parison of 1H NMR spectra
s
of 7 in (A.) 100%
1
DMS
SO-d6, (B.) 70%
Figure 2.2.
DMSO-dd6/30% D2O,, and (C.) 300% DMSO-dd6/70% D2O.
O Spectra were
w
obtainedd roughly 155 min
after prepparing the saample. Keyy signals inddicative of sppirolactam formation
f
arre denoted by red
arrows. Note
N
the inccrease in thee relative inteensities of thhe spirolactaam signals coompared to those
of compoound 7 with increased water
w
content in the solveent.
C
Conversion
of
o 7 to the spirolactam was easily noticed by the appearaance of new
w key
signals (ddenoted by red
r arrows in
i Figure 2.22). Originally chemicallly equivalennt at 1.3 ppm
m, the
gem-dim
methyls becam
me differenttiated in the spirolactam
m form suchh that two neew signals at
a 0.8
ppm andd 1.0 ppm reesult. Simillarly, the meethylene hyddrogens alsoo became chhemically distinct
from onee another in the
t spirolacttam form, shhifting from a singlet at 3.0 ppm to a pair of douublets
centered at 2.18 ppm
m and 2.38 pppm. The rellative intenssities of the spirolactam
s
signals increeased
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as more D2O was added to the saample, accom
mpanied by a decrease in
i the signalls associatedd with
compounnd 7.
N
Nicolaou
et al.
a proposed that “anilinee-type” amidde conjugatees of quinone propionic acids
(i.e. thosse containing
g a hydrogeen on the arromatic aminne) undergo spirolactam
m formation by a
specific base-catalyzzed mechanism.13 Theerefore, subsstitution of the amine hydrogen
h
w
with
a
methyl group
g
shoulld prevent spirolactam
s
formation in the present case.

To confirm
m this

hypothessis, 9 was sy
ynthesized annd its stabiliity investigaated by 1H NMR
N
in a miixture of DM
MSOd6 and D2O. It shoulld be noted from
f
the preevious work that the parra-substituennt of the arom
matic

Figure 2.3. Comp
parison of 1H NMR sppectra of 9 in (A.) 1000% DMSO-dd6, and in 70%
7
DMSO-d6/30% D2O (B.) after 15 min and (C.)
(
after 244 hours.
amine haad no influeence on spiroolactam form
mation;13 theerefore, 9 iss a suitable surrogate foor the
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methylated version of 7, because the latter could not be synthesized in sufficient quantities with
acceptable purity.
The 1H NMR spectra of 9 showed no change after 24 hours (Figure 2.3), particularly in
the region between 0–3 ppm, so it was concluded that 9 is stable in 70% DMSO-d6/30% D2O.
Thus, it was found that methylation of the aromatic amine, indeed, inhibited formation of the
spirolactam in aqueous solution.
2.3

Summary
The variously substituted simple quinones (1a–h) and quinone propionic acids (4a–h)

were synthesized and characterized for subsequent cyclic voltammetry studies (see Chapter 3).
The 4 target Q-DOPE lipids (6a–d) and their respective quinone succinimide propionate
intermediates (5a–d) were synthesized and characterized. The Q-DOPE lipids were prepared
into liposomes for encapsulation and triggered release studies (see Chapter 4).

Quinone

compounds 7 and 8 were synthesized and characterized with the intent of coupling DOPE to 8
through the carbonate carbon (eliminating 4-nitrophenol), to generate a self-immolative spacer
between the quinone and DOPE. Once prepared into PEGylated liposomes, the purpose of an
appropriate self-immolative spacer will be to extend the quinone trigger moiety away from the
bilayer surface, comparable to the PEG chains, thus possibly improving accessibility of NQO1 to
the quinone substrate. However, it was found that 7 undergoes rapid cyclization to form a
spirolactam in aqueous media, as evidenced by 1H NMR specroscopy, which defeats the purpose
of the extended spacer. To confirm the findings of Nicolaou et al.,13 9 was synthesized and its
stability investigated by 1H NMR in aqueous media, revealing that methylation of the aromatic
amine (absence of amine hydrogen) does prevent spirolactam formation.

186

2.4

References

(1)

Ong, W.; Yang, Y. M.; Cruciano, A. C.; McCarley, R. L., Redox-Triggered Contents
Release from Liposomes. J. Am. Chem. Soc. 2008, 130 (44), 14739-14744.

(2)

Borchard.Rt; Cohen, L. A., Stereopopulation Control .3. Facilitation of Intramolecular
Conjugate Addition of Carboxyl Group. Journal of the American Chemical Society 1972,
94 (26), 9175-9182.

(3)

Cressman, H. W.; Thirtle, J. R., 1-Step Synthesis of Polyalkyl-2-Iodo-P-Benzoquinones.
J. Org. Chem. 1966, 31 (4), 1279-1281.

(4)

Smith, L. I.; Wiley, P. F., The Reaction between Quinones and Metallic Enolates. 20. 2nd
Paper on Bromotrimethylquinone and Sodio Malonic Esters. J. Am. Chem. Soc. 1946, 68
(5), 887-893.

(5)

Carpino, L. A.; Triolo, S. A.; Berglund, R. A., Reductive Lactonization of Strategically
Methylated Quinone Propionic-Acid Esters and Amides. J. Org. Chem. 1989, 54 (14),
3303-3310.

(6)

Cichewicz, R. H.; Kenyon, V. A.; Whitman, S.; Morales, N. M.; Arguello, J. F.; Holman,
T. R.; Crews, P., Redox Inactivation of Human 15-Lipoxygenase by Marine-Derived
Meroditerpenes and Synthetic Chromanes: Archetypes for a Unique Class of Selective
and Recyclable Inhibitors. J. Am. Chem. Soc. 2004, 126 (45), 14910-14920.

(7)

Reddy, T. S.; Narasimhulu, M.; Suryakiran, N.; Mahesh, K. C.; Ashalatha, K.;
Venkateswarlu, Y., A Mild and Efficient Acetylation of Alcohols, Phenols and Amines
with Acetic Anhydride Using La(No3)(3)Center Dot 6h(2)O as a Catalyst under SolventFree Conditions. Tetrahedron Lett. 2006, 47 (38), 6825-6829.

(8)

Kumadaki, I.; Hirai, M.; Koyama, M.; Nagai, T.; Ando, A.; Miki,
Trifluoromethylation of Tocopherols. Synth. Comm. 1989, 19 (1-2), 173-177.

(9)

Singh, I.; Prasad, A. K.; Sharma, A. K.; Saxena, R. K.; Olsen, C. E.; Cholli, A. L.;
Samuelson, L. A.; Kumar, J.; Watterson, A. C.; Parmar, V. S., Synthetic and Novel
Biocatalytic Resolution Studies on (+/-)-5/6/7-Acetoxy-4-Aryl-3,4-Dihydrocoumarins.
Bioorg. Med. Chem. 2003, 11 (4), 529-538.

(10)

Volpato, M.; Abou-Zeid, N.; Tanner, R. W.; Glassbrook, L. T.; Taylor, J.; Stratford, I.;
Loadman, P. M.; Jaffar, M.; Phillips, R. M., Chemical Synthesis and Biological
Evaluation of a Nad(P)H : Quinone Oxidoreductase-1-Targeted Tripartite Quinone Drug
Delivery System. Mol. Cancer Ther. 2007, 6 (12), 3122-3130.

(11)

Pessah, N.; Reznik, M.; Shamis, M.; Yantiri, F.; Xin, H.; Bowdish, K.; Shomron, N.; Ast,
G.; Shabat, D., Bioactivation of Carbamate-Based 20(S)-Camptothecin Prodrugs. Bioorg.
Med. Chem. 2004, 12 (8), 1859-1866.

187

T.,

(12)

Gopin, A.; Ebner, S.; Attali, B.; Shabat, D., Enzymatic Activation of Second-Generation
Dendritic Prodrugs: Conjugation of Self-Immolative Dendrimers with Poly(Ethylene
Glycol) Via Click Chemistry. Bioconjugate Chem. 2006, 17 (6), 1432-1440.

(13)

Nicolaou, M. G.; Wolfe, J. L.; Schowen, R. L.; Borchardt, R. T., Facilitated
Intramolecular Conjugate Addition of Amides of 3-(3',6'-Dioxo-2',4'-Dimethyl-1',4'Cyclohexadienyl)-3,3-Dimethylpropionic Acid. 2. Kinetics of Degradation. J. Org.
Chem. 1996, 61 (19), 6633-6638.

188

CHAPTER 3
EVALUATION OF SIMPLE QUINONES AND QUINONE PROPIONIC ACIDS USING
CYCLIC VOLTAMMETRY AND X-RAY CRYSTALLOGRAPHY
3.1

Introduction
Chemical groups that are triggered by a variety of stimuli and can be used to initiate the

destruction or creation of active species, such as volatiles,1 prodrugs2-4 and biologicals,5-6 or
molecular assemblies—including dendrimers,7-10 polymeric micelles,11-12 and liposomes13-15—
are crucial to a variety of applications, including diagnostics, drug delivery, and sensing.
Exogenous (e.g. light/radiation,14,16 hyperthermia14,17) and endogenous (e.g. low pH14,18-19 and
enzymes14,20-21) stimuli are typically used to activate trigger groups. In particular, for diagnostics
and drug delivery, endogenous stimuli can offer high specificities (Km) and sensitivities (Vmax,
enzyme turnover rate), if appropriate trigger groups exist so as to take full advantage of diseased
site characteristics.
In the case of enzymatically-activated trigger groups, high specificity and sensitivity of
trigger group removal/modification should be possible by tuning the molecular structure of the
trigger group.2,22

Our immediate interest was in building a collection of quinone-based

trimethyl-lock23 cyclization groups that undergo cyclization/target release upon triggered
reduction by chemical agents13 and NAD(P)H:quinone oxidoreductase type 1 (NQO1),24 an
enzyme that is upregulated in numerous cancer cell lines and tumors.25 The specificity and
sensitivity of quinone trigger group removal is hypothesized to be a function of the rate of
reduction/cyclization and dependent upon the reduction potential of the quinone to hydroquinone
process. Knowledge about these quinone trigger groups will broaden the scope and capabilities
of enzyme-initiated liposome contents delivery,14 latent fluorophore imaging,26 and reagent
delivery in microfluidic devices.27
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To that end, the specific aim was to tune the reduction potential of quinone triggers by
substitution on the quinone ring without disturbing the geometry of the trimethyl lock. With
these tunable quinone triggers in hand, we should be able to make highly sensitive the human
NQO1 reduction of the quinone and also avoid non-specific quinone reduction by other
adventitious reducing agents present in vivo.
In order to more fully define the utility of quinone trigger groups in development of
enzyme-based prodrugs3 or redox-responsive macromolecular/supramolecular (e.g. dendritic7-8
and liposomal13) delivery and imaging26 systems, we determined the quinone trigger group
reduction potentials from linear-sweep voltammetry in buffered aqueous, near-physiological pH
solutions. By careful selection of the quinone trigger group, it should be possible to program the
reduction sensitivity and specificity of responsive assemblies and prodrugs. For example, the
reduction potential of the FAD center of rat NQO1 is −0.159 V vs. standard hydrogen
electrode (SHE);1 although the rate of select substrate reduction by human NQO1 is 2–5 times
slower than that of the rat variant,1 we anticipated that the rate of quinone reduction by human
NQO1 will, in general, increase with increasingly positive reduction potential. In addition, it is
important to tune the reduction potential of the quinone-based triggers so as to decrease or
prevent their non-specific reaction with adventitious reducing agents present in a given
application environment, such as glutathione (−0.22 V vs. SHE)1 or ascorbate (0.051 vs. SHE).2
3.2

Experimental Section

3.2.1

Materials and Methods
Synthetic protocols of the simple quinones (1a–h) and quinone propionic acids (4a–h)

used in cyclic voltammetry (CV) experiments and characterized by X-ray crystallography are
described in Chapter 2. CV experiments were performed by Maria Fabiana Mendoza (colleague)
using a computer-controlled EG&G PAR model 273A potentiostat and a three-electrode setup
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that incluuded a (prettreated) glasssy carbon working
w
eleectrode (A = 0.07 cm2, CH Instrum
ments,
Austin, TX),
T
a homeemade 99.9%
% platinum counting
c
eleectrode (d = 0.05 cm), and Ag/AgCll (3.0
M KCl, CH Instrum
ments) referennce electrodde. The worrking electroode was pollished only once,
prior to its
i electroch
hemical pretrreatment, onn a Buehler microcloth
m
w 1 microon alpha aluumina
with
slurry miicropolish. Pretreatmen
P
nt of the worrking electroode was achiieved by appplying +1.5 V for
10 min, a method thaat essentiallyy serves to eliminate
e
anyy electrochem
mically-activve species on
o the
surface of
o the electro
ode that mayy interfere with
w data colllection.28 Sccans were coonducted at a rate
of 0.1 V s−1 at room
m temperaturre in a 0.01 M K2HPO4/0.1 M KN
NO3 (pH 7.1)) buffer soluution.
X-ray crrystallograph
hic data wass collected by Dr. Frannk Fronczekk (X-RAY Facility)
F
usiing a
Nonius KappaCCD
K
(with
(
Oxfordd Cryostream
m) instrumennt equipped with molybbdenum radiaation.
Oak Ridgge Thermal Ellipsoid Pllot (ORTEP)) program was
w used for crystal struccture illustraations
(by Dr. Fronczek).
F
3.2.2

X
X-ray
Crysta
al Structurees (ORTEPss)

Figure 3.1.
3 ORTEP crystal struccture of 4a.
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Figure 3.2.
3 ORTEP crystal struccture of 4b and
a its dimerr.

3 ORTEP crystal struccture of 4c and
a its dimerr.
Figure 3.3.
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Figure 3.4.
3 ORTEP crystal struccture of 4d.

3 ORTEP crystal struccture of 4e and
a its dimerr.
Figure 3.5.
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Figure 3.6.
3 ORTEP crystal struccture of 1h.
3.3

R
Results
and Discussion
D

3.3.1

E
Electrochem
mical Properrties of Quin
nones Usingg Cyclic Voltammetry
T reduction
The
n potentials Ep,c of simpple quinones 1a–h and quinone
q
proppionic acids 4a–h

are summ
marized in Table
T
3.1. As
A anticipatted, the reduuction potenntials of the quinone trigggers
possessinng the trimeethyl lock (Y
( = R3 = Me; 4a–b, 4e–h) thatt have electtron-withdraawing
substitueents at R1 were
w
more positive
p
(eassier to reducce) than thoose having electron-don
e
nating
groups att R1, with feew exceptionns. Of this group,
g
we expected the dimethoxy--substituted 4h
4 to
have the most negattive reductioon potential and the broomo derivatiive 4e to bee the most easily
e
ved Ep,c of the
t bromo derivative
d
4ee (−0.07 V) was
w roughlyy the same as
a the
reduced. The observ
fo
for thee simple quiinones 1f annd 1g
hydrogenn variant 4a (−0.05 V). A similar trend was found
versus 1cc, indicating
g that the haalogenated quinones
q
werre more elecctron-rich thhan expectedd. In
fact, Novvak and Kov
vač reportedd that the coore π-orbitalls of 2,6-dibbromoquinonne-4-chloroiimine
contain more
m
halogeen lone pair character thhan its chloro-substituteed counterpaart, meaningg that
bromine’’s out-of-plaane lone paiirs were conntributing electron
e
denssity to the core
c
π-orbittals.29
Furtherm
more, they fo
ound strong resonance interactions
i
between thee iodine subbstituents annd the
2
quinone core
c
of 2,6-d
diiodo-p-bennzoquinone.29
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Table 3.11. Electroch
hemical reduuction potenttialsa for quiinones 1a–h and 4a–h.
compound
comppound
Ep,c (V) vs. SHE
Ep,c (V) vs.
v SHE

0.30

−0..05

0.20

−0..28

0.14

−0..03

0.06

−0..07

0.19

−0..07

0.13

−0..24

0.11

−0..07

0.17

−0..11

a

Potentiaal scans werre conductedd at a rate of
o 0.1 V s−1 at room tem
mperature inn pH 7.1 0.001 M
K2HPO4/0.1
/
M KNO
O3 buffer sollution using a glassy caarbon electroode and Ag/A
AgCl (3 M KCl)
referencee.
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Perhaps the most intriguing result in the trimethyl lock series (Y = R3 = Me; 4a–b, 4e–h)
was the unexpectedly high reduction potential of the dimethoxy species 4h; a similar result was
obtained for the simple dimethoxy-quinone 1h. We anticipated that 1h and 4h would have very
negative reduction potentials due to resonance effects from both methoxy groups. However, it
has been shown that steric interactions between adjacent methoxy substituents on quinones result
in one methoxy group being out of plane, thereby inhibiting the full resonance effect.29-32
Consequently, the dominating force of the out-of-plane methoxy oxygen in 1h and 4h was
inductive.
The quinone reduction potential was found to be more negative by roughly 0.2–0.3 V
when the trimethyl-lock motif was present for structurally similar compounds. For example,
comparison of 4a and 1c led to an observed −0.19 V difference, while it was −0.34 V for 4b vs.
1d, −0.20 V for 4e vs. 1f, −0.18 V for 4g vs. 1g, and −0.28 V for 4h compared to 1h. From these
results, we hypothesized that the trimethyl-lock motif affects the planarity of the quinone ring
such that there exists a more localized quinone π-system that is, in general, more difficult to
reduce than its non-trimethyl-locked counterpart.
3.3.2

X-ray Crystallographic Analysis of Quinones
Although the conformation(s) of the quinone propionic acids is/are different in solution,

X-ray crystallographic analyses of trimethyl-locked quinone propionic acids of high crystal
quality (4a, 4b, and 4e) were conducted (Table 3.2) in order to approximate the effect of the
trimethyl lock on the planarity of the quinone ring,. For ease of following assigned geometric
parameters, see Figure 3.7 for letter designations of each atom in the substituted trimethyl-locked
propionic acids.

In a planar system, torsion angles a–b–c–d and a–f–e–d should be ~0°;

however, the latter torsion angle for compounds 4a (R1 = H), 4b (R1 = CH3), and 4e (R1 = Br)
significantly deviated from planarity by 21.1°, 23.4°, and 18.49°—all very similar, comparable
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values between these compounds. This non-planarity resulted from the strain imposed on the
quinone ring by the trimethyl lock, thus restricting conformational freedom of the propionic side
chain and forcing it to bend back around toward the g–a carbonyl. In turn, this caused the
carbonyl adjacent to the trimethyl lock to be pushed out of plane, as noted by the g–a–b–c and g–
a–f–e torsion angles of 4a, 4b, and 4e that deviated from the ideal 180° by ~22–38°. Thus, the
presence of the trimethyl-lock moiety led to “warped” quinone systems that were more difficult
to reduce by 0.2–0.3 V than their non-trimethyl-locked analogues.
Table 3.2. Torsion angles (°) from X-ray crystallography dataa for quinone propionic acids.
quinone propionic acids
torsion
angleb (°)
g–a–b–c
g–a–f–e
a–b–c–d
a–f–e–d
i–d–c–b
i–d–e–f

idealc
(°)
180°

0°

180°

4a

4b

4e

−157.25 (10) −158.16 (13)

4c

4d

−151.43 (11) −177.44 (10)

178.28 (13)

146.25 (9)

145.00 (13)

142.43 (10)

175.86 (10)

−178.12 (12)

0.54 (14)

2.1 (2)

−0.44 (15)

1.40 (15)

−0.2 (2)

21.10 (12)

23.40 (18)

18.49 (14)

1.64 (15)

−0.09 (18)

174.63 (9)

175.54 (13)

170.24 (10)

176.83 (10)

−179.06 (13)

173.55 (9)

170.56 (13)

180.00 (10)

−178.44 (10)

179.22 (12)

a

Parameters were determined from CIF data using CrystMol software. Estimated standard
deviations are given in parentheses next to each calculated value. bRefer to Figure 3.7 for letter
designations of bond sequences. cIdeal torsion angles were adapted from Wang et al.33
It is significant to note that there did not appear to be a correlation between the identity of
the R1-substituent (–H, –Me, –Br) and the trimethyl-lock-induced structural changes, as the
results were all similar between these compounds.

Thus, we concluded that the observed

differences in reduction potential for 4a–b and 4e–h were due to electronic effects imparted
by R1. This tunability has important implications with regard to the specificity and sensitivity of
trimethyl-locked quinone propionic acid trigger group reduction/removal as catalyzed by NQO1.
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Figure 3.7. Letter designations for each atom in the quinone propionic acids.
By contrast, the torsion angles for compounds 4c and 4d, which do not contain the TML,
were more on par with the ideal values (Table 3.2). The torsion angles g–a–b–c and g–a–f–e for
these two compounds only deviated by 3.35° and 1.80°, respectively, from the ideal 180°. The
planarity of both the quinone ring and the g–a carbonyl remained intact without the TML to
impose significant strain on the system.
The “near-attacking conformation” (NAC) as described by Lightstone and Bruice34, and
then again by Wang et al.,33 is also important to our TML-catalyzed cyclization process. The
directionality and distance of the nucleophilic oxygen (g) to the carbonyl carbon (o) of the
propionic acid is critical for the NAC and efficient cyclization to form the lactone. Angle g–o–p
in Table 3.3 best describes the relative directionality of the relevant atoms prior to reduction,
which ideally should be about 90°.33 The presence of the TML in compounds 4a, 4b, and 4c
clearly promoted formation of the NAC by reducing the number of unproductive conformers and
bringing the angle within about 3° of the ideal 90° for each. By contrast, compounds 4c and 4d
(no TML) deviated by about 19° and 14°, respectively. Angle a–g–o describes the relative
directionality after reduction of the quinone to the hydroquinone, which ideally should be about
90–120°.33-34 With the exception of 4d, all of the compounds deviated from the ideal by at least
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10°, regardless of the presence or absence of the TML. Wang et al. also observed deviations of
about the same magnitude but concluded that these deviations were relatively small given the
dynamic motions of molecules in solution.33 There was no apparent reason for 4d’s exception to
this trend; however, its relatively good directionality was thwarted by the long distance (4.549 Å)
between the attacking oxygen (g) and the electrophilic carbon (o).
Table 3.3. Intramolecular reaction angles (°) and distances (Å) from X-ray crystallography dataa
for quinone propionic acids.
quinone propionic acids
angleb (°)

idealc (°)

4a

4b

4e

4c

4d

a–g–o

90–120°

76.5 (1)

73.9 (1)

78.1 (1)

77.7 (1)

88.5 (1)

g–o–p

~90°

93.3 (1)

93.0 (1)

86.7 (1)

70.6 (1)

103.7 (1)

distanceb (Å)

idealc (°)

4a

4b

4e

4c

4d

g–o

≤3.2 Å

3.046 (1)

3.187 (2)

2.966 (1)

3.705 (1)

4.549 (2)

l–m

2.538 Å

2.541 (1)

2.531 (2)

2.546 (2)

2.493 (1)

n/a

a

Parameters were determined from CIF data using CrystMol Software. Estimated standard
deviations are given in parentheses next to each calculated value. bRefer to Figure 3.7 for letter
designation of bond sequences. cIdeal angles and distances were adapted from Wang et al.33
A non-bonded distance of less than or equal to 3.2 Å between the oxygen (g) and the
carbon(o) is also needed for the near-attacking conformation.34 The TML-containing compounds
4a, 4b, and 4e all possessed g–o distances commensurate with the ideal.

As expected,

TML-lacking compounds, 4c and 4d, did not have adequate g–o distances to meet the criteria of
a NAC.

The non-bonded l–m distances between the geminal methyl carbons for the

TML-containing compounds (4a, 4b, 4e) also fit the ideal 2.538 Å, which is observed for
crystalline alkanes, such as C20H42.
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3.4

Conclusions
In summary, we have developed a family of redox-responsive intramolecular cyclization

groups whose members can be selectively and specifically triggered as a result of their chemical
structure. Interestingly, simple quinones and quinone propionic acids containing a halogen
substituent (i.e. 1e–g and 4e, g) had lower reduction potentials than was anticipated, versus their
hydrogen-counterparts, which suggested that the halogens were not as electron-withdrawing as
expected. The reasons for this observed result are still debated; however, it seems that the
halogens may have been pushing more electron-density into the ring through resonance
interactions, as reported by some germane literature findings.29

Even though X-ray

crystallography only reveals information about chemical structure in the solid state, the results
did give some idea about possible conformation(s) of the quinone propionic acids in solution.
The presence of a trimethyl lock at the 6-position of the quinone propionic acid resulted in a
general structure wherein the quinone ring was puckered or “warped” and was independent of
the substituent at the 2- or 3-positions of the quinone ring (R1 and R2). However, it was found
that the R1 and R2 substituents dictated the reduction potential of the quinone trigger group,
thereby providing a ~0.2 V range for the triggering of the cyclization process. This range of
reduction potentials provides access to tunable quinone trigger group activation by a human
quinone oxidoreductase (hNQO1) known to be upregulated in a variety of cancers.35-39
Furthermore, the tunable nature of the quinone trigger group resulted in control over non-specific
triggering by adventitious reducing agents. Work has been underway in our group to study the
use of the trimethyl-locked quinone propionic acid triggers in enzyme-initiated liposome
contents delivery, latent fluorophore imaging, and reagent delivery in microfluidic devices.
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CHAPTER 4
ENCAPSULATION AND TRIGGERED RELEASE STUDIES OF VARIOUS Q-DOPE
LIPOSOMES USING FLUORESCENCE SPECTROSCOPY
4.1

Introduction
The ability of a paramedic to respond to an emergency initially depends on the

ambulance to transport them safely to the scene; therefore, it is important for the ambulance to
remain intact (i.e. avoid wrecks) while en route. Likewise, maintaining the integrity and stability
of the liposome delivery vehicle is of primary importance until the diseased site is reached.
While the total pharmacological profile of a liposomal drug formulation is characterized by the
adsorption, distribution, metabolism, and excretion (ADME) of both the encapsulated drug and
the liposome excipient, the therapeutic efficacy of the drug cargo mainly depends on the
pharmacokinetics and tissue distribution of the liposome.1 Moreover, drug bioavailability also
depends on the total amount of drug released from the liposome carrier.2 Thus, it is important to
understand liposome pharmacokinetics and drug pharmacodynamics such that drug release rates
can be tailored to fit the efficacy profile of the drug cargo.1-2
Therapeutically-optimized drug release rates are essential for maximizing the benefits of
liposomal drug formulations.1 As a case-in-point, Johnston et al. showed that moderate release
rates were more efficacious for liposomal formulations that contained cell cycle-specific drugs,
such as vincristine.2-3 With prolonged exposure to cells, vincristine has been shown to cause
greater cell death in vitro and have increased antitumor activity in vivo.3-9 Therefore, optimizing
drug release rates from liposome carriers is an important aspect in order to fully exploit the
therapeutic effect of the carried drug. To this end, it is important to understand how a liposome
excipient destabilizes and releases it cargo. Moreover, inclusion of a responsive element into the
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liposome bilayer provides a way to control the permeability of the membrane and, thus, the rate
of contents release.1
On a related topic, enzymatically-triggered liposome delivery systems also require
optimum conditions in order to achieve site-specific drug release—that is, specificity of the
targeted enzyme and the substrate (a component of the liposome) must be ideal such that drug
delivery is triggered only by that enzyme. To date, the two main enzymes studied to initiate
liposomal drug release extracellularly are secretory phospholipase A2 type IIA (sPLA2–IIA) and
matrix metalloproteinase–2 and –9 (MMP–2 and MMP–9), which represent the opposite ends of
the spectrum in terms of substrate specificity.
sPLA2–IIA catalyzes the hydrolysis of the sn–2 ester bond in glycerophospholipids,
particularly those that are in an aggregated form (e.g. liposomes and micelles) and possess a net
anionic charge.10-13

Neutral membranes composed of zwitterionic lipids, such as

phosphocholines, induce virtually no enzymatic action from sPLA2–IIA.11-13 While the topology
of the membrane surface (i.e. lipid composition, morphology/arrangement, membrane charge)
with which sPLA2–IIA acts is important to the activity of this enzyme,11-12,14 its substrate
specificity is still more general compared to that of MMP–2 and MMP–9.
Specialized

lipopeptides

containing

the

amino

acid

substrate

sequence,

L-prolyl-L-leucyl-glycyl-L-leucine (AcProLeuGlyLeu), are required for MMP-triggered liposome

destabilization.2,15 In fact, Kline et al. found that both MMP–2 and MMP–9 are highly sensitive
to the structure and orientation of certain AcProLeuGlyLeu residues.15 Strong hydrogen bonds
in the active sites of these MMPs are responsible for their increased substrate specificity.15
Small changes or deviations in the molecular composition of the amino acid substrate sequence
result in loss of interaction with MMP–2 and/or MMP–9.15
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The quinone trigger, used in the redox-active liposome delivery vehicles described
herein, provides a measure of tunability that is bipartite: (1) the stimuli-responsive
destabilization behavior and (2) the enzymatic selectivity can both be adjusted according to
different functionalities present on the quinone ring. In this way, release rates of entrapped cargo
can be optimized, and enhanced selectivity for the targeted enzyme can be achieved. The
additional degree of tunability that these liposomes offer makes possible the realization of a
moderately sensitive enzymatically-triggered system via quinone electronics, as opposed to
liposomes activated by sPLA2–IIA (not very substrate specific) or MMP–2 and –9 (very
substrate specific).
4.2

Experimental Section

4.2.1

Molar Extinction Coefficient Determination
To determine the molar extinction coefficients (ε) of the Q-DOPE lipids, ca. 1–3 mg of

the lipid were dissolved in 10–25 mL of chloroform to make the stock solution. A serial dilution
of the stock solution yielded concentrations that ranged from ca. 0.015–0.12 mM.

The

absorbance values of these dilutions were obtained spectrophotometrically using a Varian Cary
50 Bio UV-Visible Spectrophotometer and then plotted versus concentration. The slopes of each
graph were multiplied times 103 to yield the ε (in M−1 cm−1) for each Q-DOPE lipid.
To determine the molar extinction coefficients of the Q-DOPE liposomes, the lipids had
to first be prepared into empty (no encapsulated calcein) liposomes (see 4.2.2 below), except ca.
2–5 mg of the lipid were dissolved in buffer at a concentration of 1 mg mL−1. Then, this solution
was diluted 10-fold to generate the stock solution, from which serial dilutions were made that
ranged from ca. 0.016–0.10 mM. The absorbance values of these dilutions were obtained
spectrophotometrically, as described above, and the ε for each Q-DOPE liposome was extracted
from the absorbance versus concentration plots.
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4.2.2

Liposome Preparation16
Liposomes were prepared according to the “lipid thin-film and extrusion” method,17-18 as

previously reported by our group.16 Q-DOPE lipid (1–3 mg) was dissolved in chloroform (2–3
mL) in a 25-mL round-bottom flask, and the lipid solution was evaporated to a thin lipid film
using a stream of argon gas. The films were dried under high vacuum for 1 h and redissolved in
pH 7.4, 50 mM phosphate buffer/75 mM KCl at a concentration of 1 mg mL−1. The solution was
aged (1 h) with occasional vortexing (ca. 15–30 s at 20 min intervals), after which it underwent 6
freeze-thaw cycles using a dry ice/acetone bath, followed by extrusion (14 times) at ambient
temperature through a 100-nm pore Whatman Nuclepore polycarbonate track-etched membrane
using an Avanti Mini-Extruder (Avanti Polar Lipids, Alabaster, Alabama). For the preparation
of calcein-loaded liposomes, the entire “extrusion” procedure described above was used, except
that the buffered solvent also contained dissolved calcein (40 mM, Sigma-Aldrich, Milwaukee,
WI).

Following

extrusion,

the

nonencapsulated

dye

was

separated

from

the

liposome-encapsulated dye by gel filtration of the extruded solution through a column of
Sephadex G-75 resin (GE Healthcare BioSciences, Piscataway, NJ). Separate gel-filtration
columns were used for each individual Q-DOPE liposome composition: to decrease non-specific
adsorption, non-calcein-encapsulated liposomes were passed through the columns prior to their
initial use.
4.2.3

Calcein Release Experiments16
The purified calcein-loaded liposomes were diluted with buffer to achieve an arbitrary

concentration that was based on the absorbance (Varian Cary 50 Bio UV-Visible
Spectrophotometer) of the encapsulated calcein at 487 nm, typically maintained between
0.08–0.1; Absorbance values for the liposome-encapsulated calcein were kept ≤ 0.1 to avoid
saturation of the detector after calcein release. Then, 3 mL of this diluted solution were put into
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a 4-sided transparent quartz cuvette and degassed for a few min. Fluorescence intensities
(λex = 490 nm, λem = 515 nm) were recorded using a Perkin-Elmer LS 55 Fluorescence
Spectrometer with a PTP-1 Fluorescence Peltier System and PCB 1500 Water Peltier System.
Excitation and emission slit widths were set to 5.0 nm each. Baseline fluorescence (desired
relative intensity < 350 to avoid saturation of detector upon dithionite addition) was obtained for
0.5–1 hr to monitor the stability of liposomes in solution. A degassed solution of ca. 2.5–3.0 mg
of Na2S2O4 (85%, Sigma-Aldrich) in 1 mL of buffer was prepared and an appropriate aliquot
(normally, 17–21 µL) was injected into the cuvette to attain 0.3 mmol of added Na2S2O4. After
injection, the cuvette was vigorously shaken, and the initial “trigger” time was noted. Data was
collected for 0.10 s at 1 min intervals over a maximum 25-hour period of time. To stop the
experiment, and establish 100% calcein release, 15 µL of a 15% (w/v) Triton X-100 (SigmaAldrich) solution was added to the cuvette, and data collection continued for an additional 10
min.
4.2.4

Liposome Characterization16
Dynamic light scattering measurements were obtained from backscatter intensities (173°,

633 nm red laser) obtained at 25 °C with calcein-free liposomes using a Zetasizer Nano ZS
(Malvern Instruments, Worcestershire, U.K.) particle size analyzer; DLS intensity distributions
of calcein-encapsulated liposomes were previously found to be indistinguishable from those of
the calcein-free liposomes.16 Zeta potentials of calcein-free liposomes were obtained using the
same Zetasizer Nano ZS instrument with closed, folded capillary zeta potential cells.
4.3

Results and Discussion

4.3.1

Molar Extinction Coefficients of Q-DOPE Liposomes
Originally, the purpose of determining the molar extinction coefficient (ε) of each

Q-DOPE liposome was to calculate the concentration of the liposome samples in the calcein
209

release experiments. If this method for determining the liposome concentration was accurate, it
could be used to adjust the amount of sodium dithionite added to the liposome samples such that
desired molar ratios of dithionite-to-lipid could be achieved. The absorbance values recorded
and used to generate the dilution curves correspond to the π–π* transition of the quinone.
Because the effective, local concentration of quinone in liposomal form (versus as individual
Q-DOPE lipids) is different due to their close proximity to each other in the bilayer, the molar
extinction coefficient of the free Q-DOPE lipids dissolved in chloroform was also determined, as
a form of verification. The molar extinction coefficients of the Q-DOPE lipids and liposomes
are given in Table 4.1.
Table 4.1. Molar extinction coefficients of Q-DOPE lipids and liposomes.
molar extinction coefficient, ε (M−1 cm−1)
Q-DOPE composition

lipidsa

liposomesb

QH–DOPE (6a)

11,200±200

11,000±200

QMe–DOPE (6b)

n.d.c

5,500d

QBr–DOPE (6c)

9,380±30

6,560±30

QnPrNH–DOPE (6d)

8,070±70

9,320±30

a

Lipids were dissolved in chloroform. bLiposomes were prepared in pH 7.4, 50 mM
phosphate buffer/75 mM KCl. cNot determined. dDetermined by Forsythe and McCarley,
unpublished results.
From these results, it was clear that the formulation of Q-DOPE lipids (i.e. as free lipids
or in liposomal form) does affect their spectrophotometrically-determined molar extinction
coefficients. With the exception of QH–DOPE, the molar extinction coefficients of the lipids and
the liposomes varied considerably for each Q–DOPE. Therefore, it was concluded that this
method is not accurate or reliable for determining the liposome concentration in the calcein
release experiments. (As a result, it was deemed unnecessary to determine the molar extinction
coefficient for the QMe–DOPE lipids in chloroform.) Instead, the concentrations of the diluted
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liposomes were based on the absorbance of encapsulated calcein at 487–490 nm and maintained
between absorbance values 0.08–0.1 (Table 4.2), such that the relative liposome concentration
was approximately the same between trials.
4.3.2 Release Behavior of Q-DOPE Liposomes
The purified calcein-loaded Q-DOPE liposomes were diluted so that, upon triggered
release, the concentration of free calcein did not cause an increase in fluorescence signal high
enough to saturate the detector. The relative concentrations of the diluted liposome samples
were determined based on the absorbance of the encapsulated calcein at 487–490 nm, and these
absorbance values were maintained between 0.08–0.1 in order to keep the liposome
concentrations relatively constant between trials (Table 4.2). A fellow colleague had already
conducted calcein release experiments with QMe–DOPE liposomes, so these liposomes were
prepared and analyzed again as a “benchmark” or standard to which the other liposomes’
behaviors were compared and to ensure that the experimental procedure was being executed
properly and reproducibly.
Upon injection of sodium dithionite (the reducing agent), the redox-active liposomes
became destabilized and release of the entrapped calcein ensued at different rates that were
characteristic of their individual Q-DOPE lipid composition. In other words, each type of
Q-DOPE liposome had its own distinct calcein release profile, which can be seen in Figure 4.1.
Qualitatively, QMe–DOPE and QnPrNH–DOPE appeared to have similar release behaviors, while
QH–DOPE and QBr–DOPE seemed to destabilize much differently.
To quantitatively compare the 4 different Q-DOPE liposomes, average lag times and
average t50% values were determined (Table 4.3). The “lag time” refers to the contraction event
in which there is a decrease in fluorescence signal after injection of the reducing agent. The lag
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time was defined as the time elapsed between two distinct events: the initial injection of
dithionite and the contraction maximum (i.e. the lowest fluorescence intensity reached).
Table 4.2. Resulting absorbance values for the final dilutions of the calcein-loaded Q-DOPE
liposomes. Arbitrary concentrations of the diluted liposomes were based on the absorbance of
encapsulated calcein at 487–490 nm and maintained between 0.08–0.1. The other absorbance
values listed at wavelengths < 300 nm correspond to the quinone moiety and are provided for
completeness. Each trial corresponds to a calcein release experiment.
wavelength (nm), absorbance
lipid composition of
liposome

trial 1

trial 2

trial 3

trial 4

QH–DOPE (6a)

249, 0.335
487, 0.0832

249, 0.360
487, 0.0790

249, 0.352
487, 0.0876

n.d.a

QMe–DOPE (6b)

490, 0.0984

490, 0.0952

n.d.a

n.d a

QBr–DOPE (6c)

270, 0.756
487, 0.093

269, 0.736
487, 0.092

270, 0.745
487, 0.104

280, 0.833
498, 0.102

QnPrNH–DOPE (6d)

226, 0.337
291, 0.175
487, 0.122

226, 0.257
293, 0.135
487, 0.0920

226, 0.349
291, 0.182
487, 0.118

n.d.a

a

Not determined because no further trials were needed: the liposome release behaviors
corroborated each other in the preceding trials.
It has been hypothesized that the liposome surface undergoes dehydration upon cleavage of the
quinone stabilizer from the DOPE lipid, which is a necessary step in order overcome hydration
repulsive forces that prevent the close approach of apposing liposome bilayers and subsequent
contact-driven rupture.19-20 As a result, this dehydration event causes a shrinkage or contraction
of the liposomes that increases the self-quenching concentration of the calcein, thus decreasing
the observed relative fluorescence intensity. The QBr–DOPE liposomes had the shortest average
lag time, while the QH–DOPE liposomes had the longest average lag time. All of the average lag
times were statistically different, as there was no overlap within the experimental error, and did
not vary significantly between trials (low standard deviations).
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Figure 4.1. Calcein release profiles (normalized) of various Q-DOPE liposomes as determined
by fluorescence emission spectroscopy (λex = 490 nm, λem = 515 nm). Each trace represents the
typical release behavior observed for each Q-DOPE liposome composition.
The “t50%” was defined as the time at which 50% of the encapsulated calcein was
released. It should be noted that, first, all of the trials for each Q-DOPE liposome had to be
normalized (set to 100%) to the total amount of calcein actually released, because not every trial
resulted in 100% calcein release—the cause of which is currently unknown. While the reason(s)
behind this variation in calcein release can only be speculated, it is suspected that a few different
factors are involved. The nature of the Q-DOPE lipid appears to have a substantial effect: the
total percentage of calcein release (not normalized, raw data) from the QBr–DOPE and
QH–DOPE liposomes varied the most between individual trials, while the QMe–DOPE and
QnPrNH–DOPE liposomes consistently released close to 100% of encapsulated calcein in each
trial. Moreover, the more variable behavior of the QBr–DOPE and QH–DOPE liposomes was
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evidenced by the larger standard deviations of their respective average t50% values, as compared
to that of the more consistent QMe–DOPE and QnPrNH–DOPE liposomes.
Table 4.3. Average lag times and t50% of Q-DOPE liposomes.
lipid composition of liposome

average lag time (min.)

average t50% (min.)

QH–DOPE (6a)

40.3±0.6a

80.7±10.5a

QMe–DOPE (6b)

24.0, 26.0b

35.5, 38.5b

QBr–DOPE (6c)

13.0±0.8c

23.0±6.4c

QnPrNH–DOPE (6d)

18.7±2.1d

32.0±2.8d

a

Average of three trials. bTwo trials. cAverage of four trials. dAverage of three trials. Errors
expressed as ± one standard deviation are given next to each average.
4.3.3

Average Diameters and Zeta Potentials of Q-DOPE Liposomes
To possibly help explain the results/trends observed during the calcein release

experiments, the Q-DOPE liposomes were characterized by dynamic light scattering, from which
their average diameters and zeta potentials were elucidated (Table 4.4). Again, the QMe–DOPE
liposomes were analyzed as a standard for comparison: a colleague had already determined an
average z-average diameter of 112.7±0.6 nm (PDI = 0.09±0.14) and average zeta potential of
−62±4 mV for QMe–DOPE liposomes in 50 mM phosphate buffer/50 mM KCl. These results
compared favorably with those presented in Table 4.4 for the QMe–DOPE liposomes.

As

expected, the Q-DOPE liposomes possessed average diameters in the 90–150 nm range, which
was within the 80–200 nm range found for similar Q-DOPE liposomes as previously reported by
our group.16
The average zeta potentials for the Q-DOPE liposomes ranged from −55 mV to −60 mV.
All of the average zeta potentials were within the error for each liposome, except that of
the QH–DOPE (−59±1 mV) and QnPrNH–DOPE (−55±2 mV) liposomes, whose error did not
overlap. The similar average zeta potential values do not seem to correlate with, or be an
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indication of, the release behavior of these liposomes. For example, even though the average
zeta potentials of the QH–DOPE and QBr–DOPE liposomes are very similar, their release
behaviors were quite different, at opposite ends of the spectrum from each other—QBr–DOPE
liposomes released entrapped calcein the fastest, while QH–DOPE liposomes had the slowest
release rates.
Table 4.4. Averagea diameters and zeta potentials of Q-DOPE liposomes.
lipid composition of
liposome

average z-avg.
diameter (nm)

average PDIb

average zeta potential
(mV)

QH–DOPE (6a)

115.6±0.2

0.06±0.01

−59±1

QMe–DOPE (6b)

113.7±0.1

0.08±0.02

−60±3

QBr–DOPE (6c)

131.0±0.4

0.07±0.02

−58±2

QnPrNH–DOPE (6d)

94.7±1.1

0.09±0.01

−55±2

a

Values in each column are averages of three trials from a single preparation. Errors expressed
as ± one standard deviation are given next to each average. bPolydispersity indexes ≤ 0.45 are
considered monodisperse.21
4.4

Conclusions
Calcein-loaded liposomes composed of 4 different lipid compositions (QBr–DOPE,

QH–DOPE, QMe–DOPE, and QnPrNH–DOPE) were prepared and diluted to arbitrary
concentrations based on absorbance (0.08–0.1) of the loaded calcein at ca. 490 nm—not
according to calculated concentrations based on their molar extinction coefficients, due to
disagreement between the ε values determined from lipids versus liposomes. The encapsulation
and triggered release behaviors of these liposomes were investigated using fluorescence
spectrometry. Qualitative comparison of the release curves between the various liposomes
revealed distinctly different behaviors, indicating that quinone substitution can be used to control
the stimuli-responsive behavior of these liposomes.

Upon addition of the reducing agent,

QBr–DOPE liposomes released the entrapped calcein the fastest, while the rate of calcein release
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from QH–DOPE liposomes was much slower. The relative release profiles of QMe–DOPE and
QnPrNH–DOPE liposomes were qualitatively the most similar and exhibited comparable t50%
values.

From the raw data, the total percentage of calcein release from QMe–DOPE and

QnPrNH–DOPE liposomes was nearly constant, at approximately 100% for each trial. More
variation in the total percentage of calcein release was observed for QBr–DOPE (50–100%) and
QH–DOPE (70–95%) liposomes between trials (data not shown).
The 4 different liposomes were all found to have similar average diameters in the
90–150 nm range.

The average zeta potentials for all the liposomes were also about the

same, ranging from −55 mV to −60 mV. Neither the z-average diameters nor the zeta potentials
seemed to correlate with the release behaviors of the liposomes. The marginally more positive
zeta potential of the QnPrNH–DOPE liposomes, compared to that of the other liposomes, indicated
that either the n-propylamino group was not protonated or scarcely protonated such that its
impact on the overall charge of the bilayer was minimal at best.
It is interesting to consider the role of the n-propylamino group in the destabilization
process, aside from its electronic (inductive/resonance) contributions to the ring. It has been
becoming evident that, upon reduction of the quinone, the rate-determining step is the
breakdown of the tetrahedral intermediate that forms as a result of the intramolecular cyclization
event. The nitrogen of the n-propylamino group may have been acting as an internal base to
catalyze this step, thus, enhancing the destabilization rate (i.e. shorter average lag time and
average t50%) of these liposomes.
Referring back to the electrochemical results in Chapter 3, it was also apparent that the
reduction potentials (Ep,c) of the corresponding quinone propionic acids did not give a clear
indication/prediction of the release behaviors of their Q-DOPE liposome counterparts. It should
be noted that the observed reduction potentials for the quinone propionic acids may not
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necessarily have reflected the same trend for the corresponding Q-DOPE lipids, or liposomes for
that matter, being chemically different entities. Therefore, while the electrochemical properties
of the simple quinones and quinone propionic acids provided some important information about
the influence of quinone substitution on the reduction potentials of these compounds, the release
behavior of the Q-DOPE liposomes cannot be predicted from these values.
4.5
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CHAPTER 5
CONCLUSIONS AND OUTLOOK
5.1

Summary
The overall goal of this research was the development of redox-active liposome delivery

agents composed of fusogenic dioleoylphosphatidylethanolamine (DOPE) stabilized with an
electrochemically-active quinone (Q) trigger moiety whose electronic structure helps control
liposome activation and rate of destabilization (payload delivery) upon interaction with a
reducing stimulus. The synthesis and evaluation of a series of water-soluble, quinone-propionic
acids (Q-COOH) by cyclic voltammetry (CV) allowed the electrochemical properties of these
compounds to be determined in aqueous media. From CV measurements, it was found that
quinone substitution with electron-donating groups displayed more negative reduction potentials;
whereas, electron-withdrawing groups caused more positive reduction potentials, in general. The
electrochemical contribution of the propionic acid side chain was more substantial when the
trimethyl-lock was present, due to steric influences that localized electron density on the quinone
ring.

The general trends and electrochemical phenomena observed for the Q-COOHs

approximated the effect of quinone substitution on the electronics of the Q-DOPE lipids. The
information learned from these CV studies also allowed careful selection of a choice few
substituted Q-COOHs for enzyme kinetics studies with NQO1 by another colleague in our
research group.

To supplement the CV findings, X-ray crystallographic analysis of all

crystalline Q-COOHs was conducted to investigate any structural variables (i.e. quinone
substituents and trimethyl-lock) that could be affecting the electrochemical results. Trialkyllocked quinones are well-known in the literature to be conformationally constrained, causing
non-planarity in regions of the quinone ring nearest to the lock.1 The X-ray results, in fact,
revealed a highly distorted quinone ring proximal to the trimethyl-locked propionic acid side
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chain. Conversely, the region of the quinone ring furthest from the lock retained a planar
configuration. From the X-ray data, it was also apparent that the substituent in the 2-position
does not sterically affect the conformation, particularly the nearby carbonyl or the propionic acid
side chain.
After learning about the electronics, structure, and enzyme kinetics of these substituted
Q-COOHs, a family of 4 different Q-DOPE lipids were synthesized: QBr–, QH–, QMe–, and
QnPrNH–DOPE. These lipids were then prepared into liposomes according to the “lipid thin-film
and extrusion” method and loaded with calcein (a fluorescent dye) to investigate the
encapsulation and triggered release behavior of the 4 different Q-DOPE liposomes using
fluorescence spectrometry. The fluorescence data was analyzed in terms of two parameters: (1)
lag time, which is the time it takes for the liposomes to reach minimum contraction after
reduction, and (2) t50%, which is the time it takes for the liposomes to release half of their
payload. From fastest to slowest, the approximate average lag time of each liposome is as
follows: QBr–DOPE (13 min.), QnPrNH–DOPE (20 min.), QMe–DOPE (25 min.), and QH–DOPE
(40 min.). The relative order is the same for t50%, and the approximate average t50% values are:
QBr–DOPE (23 min.), QnPrNH–DOPE (33 min.), QMe–DOPE (37 min.), and QH–DOPE (81 min.).
It is clear from the calcein release profiles that the nature of the quinone triggers (i.e. quinone
substitution) does affect the stimuli-responsive behavior of the liposomes and can therefore be
controlled by incorporating various functionalities onto the quinone ring. The average sizes and
zeta potentials of these Q-DOPE liposomes (no encapsulated calcein) were also measured using
dynamic light scattering (DLS) to better characterize these liposomes and possibly help explain
the fluorescence results.

It was found that all the liposomes had an average diameter of

approximately 100 nm, with the exception of QBr–DOPE that had a slightly larger average
diameter of 131 nm. The average zeta potentials for the liposomes are all about the same:
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QnPrNH–DOPE (−55 mV), QBr–DOPE (−58 mV), QH–DOPE (−58 mV), and QMe–DOPE
(−60 mV). Even though the QnPrNH–DOPE liposomes did have the most positive zeta potential,
the impact of the n-propylamino group (possibly protonated) did not have a considerable impact
on the overall charge of the bilayer.
5.2

Conclusions
The results presented in this dissertation demonstrate the ability to exercise control over

the stimuli-responsive behavior of redox-active, Q-DOPE liposome delivery agents by
incorporating various functionalities onto the quinone ring. The capacity to achieve molecularlevel manipulation of a nanosized delivery system is exceedingly important to a variety of
analytical and medical applications, but is the cornerstone of present and developing drug
delivery technologies. The electrochemical properties of a series of water-soluble Q-COOHs
(Q-DOPE precursors) in aqueous media were successfully characterized by CV and showed that
quinone substitution significantly affects the electronics of the overall molecule.

This

observation was realized in the fluorescence experiments, where the 4 different Q-DOPE
liposomes exhibited various destabilization behaviors and rates of calcein release. The synthetic
routes to the target Q-DOPE lipids share a common pathway: once the quinone trigger moieties
are synthesized as Q-COOH intermediates, their coupling to the DOPE lipid is achieved in two
subsequent steps using established protocols. Because of this convergent-type synthetic strategy,
and the fact that the trigger group is always a quinone, these Q-DOPE liposomes can easily be
modified to generate the desired stimuli-responsive behavior for any given application.
5.3

Outlook
With increasing knowledge of the tumor microenvironment and cancer cell biology, the

future of drug delivery seems to be evolving toward the development of “multifunctional
nanocarriers” that are able to recognize tumor sites and utilize differentiating characteristics of
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these diseased sites to selectively release their therapeutic payload, thus maximizing drug
efficacy and limiting systemic exposure to healthy tissues.2 While the toxicity of the nanocarrier,
itself, is a concern because of poorly-defined biological properties of nanostructures,3 no
significant in vivo toxic effects have been reported for nanocarriers, with the exception of those
that are cationic.4
In comparison to other leading nanocarriers, liposomes offer an all-inclusive approach to
drug delivery due to their versatility that comes from a variety of functional handles (e.g.
synthetic modification of lipids, blending multiple lipids together, incorporation of targeting
ligands, cholesterol, non-immunogenic agents, to name a few).5 The redox-active, Q-DOPE
drug delivery system described herein provides an additional degree of control over its
stimuli-responsive behavior through substitution of different functional groups on Q – a task that
does not require complete synthetic overhaul or new routes. In fact, the molecular make-up of
the liposomes remains virtually constant with these slight modifications, maintaining the
Q-DOPE framework, which is advantageous from both synthetic and pharmacological
point-of-views.
According to a publication in the Journal of the National Cancer Institute, combination
chemotherapy should be the focus of future delivery systems so that multiple drugs are
distributed within tumors site-specifically and in a timely manner.6 Moreover, it is known that
some antitumor drugs are more effective when released at intermediate rates, compared to faster
or slower rates, such as vincristine that is cell-cycle specific.7-8 Therefore, our redox-active
liposomes could be envisioned as a “dual time-release” type system. For example, QH-DOPE
liposomes could encapsulate a drug to be released slowly over time, while QMe-DOPE liposomes
are loaded with a different drug to be released more quickly; administered together, these two
types of liposomes could achieve custom, time-release delivery of two different
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chemotherapeutic drugs. Similarly, two (or more) different Q-DOPE lipids could be blended
into the same liposomal formulation to alter the release rates and/or behaviors in order to achieve
optimum temporal delivery.
This whole concept of being able to control the rate of drug release through molecular
modification of the carrier is not a new idea and has been exemplified in previous
prodrug formulations, such as that of Greenwald et al.9

The pharmacokinetics of these

PEG-daunorubicin prodrug conjugates can be controlled and adjusted by careful selection of the
spacer group, trigger/linker bond, and degree of shrubbery (steric bulk) on the aromatic ring.9-10
Likewise, our redox-active Q-DOPE lipids possess several adjustable (molecular-based) facets,
in addition to Q-substitution, with which to modify the stimuli-responsive behavior of the
liposomes: length of the geminal dialkyl chains, size of the lactone ring, added elimination
products (i.e. reducing agent), and the molecular destabilization mechanism (i.e. cleavable
groups vs. lactonization).
In their 2005 review, Jung and Piizzi demarcate the gem-disubstituent effect in the
formation of small-, medium-, and large-sized rings that result from intramolecular
cyclizations.10 Even though the origin of the gem-disubstituent effect is different depending on
ring size (i.e. Thorpe-Ingold for smaller rings; conformational restriction/relief of ground-state
steric strain for medium-sized and larger rings), the rate of cyclization is enhanced by the
presence of longer and/or bulkier alkyl chains due to nonbonded interactions.10 For example,
Brown et al. found that the rate of intramolecular cyclization of a series of 4-bromobutylamines
(to their pyrrolidines) significantly increased as the size/bulk of gem-dialkyl chain increased:
cyclization of the gem-dimethyl compound (4-bromo-2,2-dimethylbutylamine) occurred at a
relative rate (krel) of 158, while the relative cyclization rate of the gem-diisopropyl compound
(4-bromo-2,2-diisopropylbutylamine) was dramatically faster at a krel of 9,190.11 To this end, the
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lactonizaation rate of our Q-DOPE
E system (thhus, the rate of liposomee opening) coould be increeased
or decreeased depen
nding on thhe choice of the side chain.

Wee have alreeady shownn that

replacem
ment of the gem-dimethy
g
yls on the propionic
p
accid side chaiin with hyddrogens results in
significanntly slower release of enncapsulated calcein.12 Another
A
sim
milar approacch to gem-diialkyl
substitutiion, which is also disscussed in the Jung and
a
Piizzi rreview,10 iss vicinal diialkyl
substitutiion (or the vic-disubstiituent effectt).

This efffect has allso been shhown to enhhance

intramoleecular cycliization ratess in compouunds contaiining vic-diaalkyl groups.13-16

Thuus, to

possibly achieve eveen faster lacctonization rates
r
versus the current gem-dimethhyl-based system,
our Q-D
DOPE lipids could be readily syntthesized usiing any of the commeercially avaiilable
variants shown
s
in Fig
gure 5.1.

5
Examp
ples of some commerciially availabble compounnds from thhe Sigma-Alldrich
Figure 5.1.
Corporattion with (A..) larger/longger gem-diallkyl chains or
o (B.) vic-diialkyl substittution.
l
ring could be adjusted
a
to either
e
increaase or
Similarly, thee size of thee resulting lactone
B
on thhe chemistryy used to atttach the sidde chain onto the
decrease the cyclizaation rate. Based
(hydro)quuinone ring (i.e. via 1,4--Michael adddition of an α,β-unsaturaated carboxyylic acid or ester),
e
any moddification wo
ould result in
i the formaation of largger lactone rings:
r
preserrving the cuurrent
syntheticc approach would
w
requirre using β,γ--unsaturated carbonyl coompounds, and
a so on. Using
U
Grignardd chemistry, synthesis off five-membeered fused laactones has previously
p
b
been
describeed by
Hillery and
a Cohen; however, thhe authors reported
r
low
w yield andd that rapid oxidation of
o the
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2,3,5-trim
methyl lactone in alkalinne media prrevented its use in kinetics studies.17 (In this same
report, a similar, more
m
stable five-member
f
red fused laactone was synthesizedd that lackedd the
phenolic oxygen and
d the methyll group in thhe 2-positionn.) Studies with ω-brom
moalkanoatees18-19
have shown that incrreasing the molecular
m
chhain length (tthereby incrreasing the siize of the lacctone
ring) deccreases the rate of lacttonization due
d to reducced probabiility of conttact betweenn the
reacting atoms. In other
o
words,, the gem-disubstituent effect
e
is reduuced as the resulting lacctone
increasess in size.
T nature of
The
o the “triggger” could also be chaanged such that the mechanism
m
o the
of
detachmeent between
n the trigger and the DO
OPE lipid iss not via redduction, but rather cleavvable
“protectinng groups” on the hydrooquinone oxxygen(s) insttead, for exaample. Suchh a system could
c
be envissaged as estterase-sensittive if the protecting groups
g
weree carbonyl-ttype compoounds
(Figure 5.2).
5

Afterr undergoingg esterase-catalyzed hyydrolysis, spontaneous lactonization
l
n and

disconneection betweeen the triggger and DOPE would occur,
o
resultting in fusogenic liposoomes.
The simpplest version
n of this typpe of system
m is depicted in Figure 5.2; althouugh, the chem
mical
composittion of the ester-based
e
p
protecting
grroups could be modifiedd to suit a particular
p
estterase
enzyme.

Figure 5.2.
5 An exam
mple of usingg ester-basedd protecting groups to guuard lactonizzation.
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Q
Quinone-meth
hide

elimiination,20

i
instead

of

lactonizatiion,

is

annother

posssible

disconneection route. Upon reduuction to thee hydroquinnone, a sponntaneous bonnd rearrangeement
occurs thhat cleaves the quinonee trigger from
m DOPE, expelling
e
a quinone-met
q
thide and caarbon
dioxide, as shown in Scheme 5.1.

Scheme 5.1. Mechan
nism of quinnone-methidde disassembbly to yield fusogenic
fu
DO
OPE liposom
mes.
T enhance the openingg efficiency of our redoox-active lipposomes, annd increase their
To
sensitivitty to NQO1
1 reduction,, a chemicaal reducing agent (i.e. hydrazine, N2H4) coulld be
incorporaated into the Q-DOPE formulationn using an azaquinone-m
a
methide (AQ
QM) eliminnation
spacer (F
Figure 5.3).21-25 Initiall reduction by NQO1 would
w
initiaate the discoonnection of
o the
quinone trigger (via lactonization), followedd by spontanneous electroonic 1,6- andd 1,4-eliminnation
cascades that liberaate the cloaaked reduciing agent and
a
DOPE (in the forrm of fusoggenic
liposomees), respectiv
vely.21 The free reducinng agent woould then be able to act as a stimuluus for
another nearby
n
quin
none trigger,, thus decreasing the nuumber of reequired enzyymatic activvation
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steps andd creating a more self-ssufficient, reedox-active liposome delivery
d
systtem—particuularly
useful in cases wheree enzyme concentrationss are relativeely low at tum
mor sites.26

Figure 5.3.
5
A modiified versionn of our currrent redox-acctive Q-DOP
PE liposomees that incluudes a
cloaked chemical
c
red
ducing agentt (hydrazine)) coupled thrrough an AQ
QM eliminatiion spacer.
5.4
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